<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Mol. Neurosci.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Molecular Neuroscience</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Mol. Neurosci.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">1662-5099</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fnmol.2025.1628567</article-id><article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group>
</article-categories>
<title-group>
<article-title>Hypoxic preconditioning increases mitochondrial respiration and H<sub>2</sub>O<sub>2</sub> production</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Bergmeister</surname>
<given-names>Lisa</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3260148"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Doerrier</surname>
<given-names>Carolina</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3067080"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fogli</surname>
<given-names>Barbara</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3070936"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Koml&#x00F3;di</surname>
<given-names>T&#x00ED;mea</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="author-notes" rid="fn0003"><sup>&#x2020;</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fischer</surname>
<given-names>Amrei</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3158596"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Springer</surname>
<given-names>Kerstin</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3159507"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Schwarzer</surname>
<given-names>Christoph</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/182233"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gnaiger</surname>
<given-names>Erich</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/611538"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label><institution>Department of Pharmacology, Medical University of Innsbruck</institution>, <city>Innsbruck</city>, <country country="at">Austria</country></aff>
<aff id="aff2"><label>2</label><institution>Oroboros Instruments</institution>, <city>Innsbruck</city>, <country country="at">Austria</country></aff>
<author-notes><corresp id="c001"><label>&#x002A;</label>Correspondence: Christoph Schwarzer, <email xlink:href="mailto:schwarzer.christoph@i-med.ac.at">schwarzer.christoph@i-med.ac.at</email></corresp><fn fn-type="present-address" id="fn0003"><label>&#x2020;</label><p>Present address: T&#x00ED;mea Koml&#x00F3;di, Department of Biochemistry, Semmelweis University, Budapest, Hungary</p></fn></author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2025-11-19">
<day>19</day>
<month>11</month>
<year>2025</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2025</year>
</pub-date>
<volume>18</volume>
<elocation-id>1628567</elocation-id>
<history>
<date date-type="received">
<day>14</day>
<month>05</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>23</day>
<month>10</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2025 Bergmeister, Doerrier, Fogli, Koml&#x00F3;di, Fischer, Springer, Schwarzer and Gnaiger.</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Bergmeister, Doerrier, Fogli, Koml&#x00F3;di, Fischer, Springer, Schwarzer and Gnaiger</copyright-holder>
<license><ali:license_ref start_date="2025-11-19">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Introduction</title>
<p>Hypoxia, an inadequate tissue oxygen supply, poses a threat to the brain, which relies heavily on oxygen for its energy requirements. However, mild oxygen deficiency triggers cellular stress, leading to a defensive state known as hypoxic preconditioning (HPC). Despite its potential as a treatment option for neurodegenerative diseases, research on preconditioning remains a challenge. Therefore, this study aimed to further explore biochemical changes induced by HPC, with a specific emphasis on mitochondria, the primary oxygen consumers.</p>
</sec>
<sec>
<title>Methods</title>
<p>We assessed the neuroprotective impact of a HPC protocol used by examining the seizure thresholds of mice. Additionally, we analyzed mitochondrial respiration under varying oxygen levels, reactive oxygen species (ROS) production, and mitochondrial morphology following HPC treatment.</p>
</sec>
<sec>
<title>Results</title>
<p>HPC treatment of mice raised their seizure threshold, indicating an enhanced resistance to epileptic seizures and highlighting the protective effects of the HPC protocol. HPC increased mitochondrial oxygen consumption and ROS production, primarily originating from Complex I. Importantly, ROS levels remaining within the physiological range potentially activate cell signaling pathways. Our findings underscored the importance of controlling oxygen at physiologically relevant intracellular tissue levels (intracellular tissue normoxia) during mitochondrial respiration measurements. Notably, HPC-treated mitochondria generally exhibited reduced oxygen consumption compared to controls under effectively hyperoxic air-saturated oxygen conditions. However, mitochondrial respiration was increased under intracellular tissue normoxia in comparison to the controls measured at air saturation. Moreover, following HPC treatment, we observed alterations in mRNA expression levels associated not just with mitochondrial dynamics but also with perinuclear mitochondrial accumulation and pro-survival signaling. Furthermore, an immediate increase in mitochondrial fusion was observed following hypoxia treatment.</p>
</sec>
</abstract>
<kwd-group>
<kwd>mitochondria</kwd>
<kwd>high-resolution respirometry</kwd>
<kwd>reactive oxygen species</kwd>
<kwd>hypoxia</kwd>
<kwd>hypoxic preconditioning</kwd>
<kwd>epilepsy</kwd>
</kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. This research was financially supported by the Austrian Science Fund (FWF) W 1206 and Oroboros Instruments.</funding-statement></funding-group>
<counts>
<fig-count count="7"/>
<table-count count="1"/>
<equation-count count="1"/>
<ref-count count="111"/>
<page-count count="20"/>
<word-count count="16169"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Brain Disease Mechanisms</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec1">
<label>1</label>
<title>Introduction</title>
<p>The brain utilizes approximately 20% of the body&#x2019;s resting metabolic energy even though it makes up just 2% of the total body mass (<xref ref-type="bibr" rid="ref57">Mink et al., 1981</xref>). Unlike muscle cells, neurons lack significant energy reserves (<xref ref-type="bibr" rid="ref67">Peters, 2011</xref>), making them highly susceptible to cognitive function declines with even brief energy interruptions. Thus, precise regulation of brain energy metabolism is vital. Both glycolysis and oxidative phosphorylation (OXPHOS) supply the brain with the required ATP (<xref ref-type="bibr" rid="ref59">Murali Mahadevan et al., 2021</xref>). OXPHOS in mitochondria generates ATP when sufficient oxygen (O<sub>2</sub>) is available, but during conditions of hypoxia, the brain switches to the less effective processes of glycolysis, resulting in reduced ATP levels (<xref ref-type="bibr" rid="ref56">Matsuda et al., 1992</xref>; <xref ref-type="bibr" rid="ref46">Kopp et al., 1984</xref>; <xref ref-type="bibr" rid="ref77">Rogatzki et al., 2015</xref>). OXPHOS accounts for up to 98% of the body&#x2019;s O<sub>2</sub> consumption (<xref ref-type="bibr" rid="ref88">Silver and Erecinska, 1998</xref>), emphasizing the dependence of mitochondria on a continuous O<sub>2</sub> supply for energy transformation.</p>
<p>The O<sub>2</sub> concentrations within the body can vary depending on the specific anatomical location and are typically lower than the levels found in the atmosphere (21%). Arterial blood typically contains O<sub>2</sub> levels of about 14%, while the brain&#x2019;s O<sub>2</sub> concentration is approximately 4%, decreasing with depth. The term &#x201C;intracellular tissue normoxia&#x201D; describes the O<sub>2</sub> pressure that is considered physiological, whereas &#x201C;functional hypoxia&#x201D; indicates O<sub>2</sub> levels that effectively limit respiration. Conversely, &#x201C;environmental normoxia&#x201D; is defined as the O<sub>2</sub> level equivalent to that found in the atmosphere (<xref ref-type="bibr" rid="ref26">Donnelly et al., 2022</xref>).</p>
<p>Functional hypoxia results in cellular adataptions of energy metabolism, mitochondrial respiration, nutrient utilization, and protein synthesis. As energy supplies are reduced during hypoxia, cells must relocate their energy metabolism and reduce ATP-consuming processes in order to survive (<xref ref-type="bibr" rid="ref49">Lee et al., 2020</xref>). Furthermore, DNA, RNA, and protein synthesis are among the first processes to be inhibited during hypoxia (<xref ref-type="bibr" rid="ref16">Buttgereit and Brand, 1995</xref>). However, the translation of transcripts that are essential for survival are enhanced, allowing cells to acclimate to low O<sub>2</sub> conditions (<xref ref-type="bibr" rid="ref99">van den Beucken et al., 2011</xref>).</p>
<p>During functional hypoxia, electron flow through the electron transfer system (ETS) slows down, discussed controversially as increasing (<xref ref-type="bibr" rid="ref93">Thomas and Ashcroft, 2019</xref>) or decreasing (<xref ref-type="bibr" rid="ref44">Komlodi et al., 2021</xref>) the risk of generating reactive oxygen species (ROS). Low levels of ROS contribute to the regulation of growth factor signaling, hypoxic responses, immune functions, and autophagy, however excessive ROS can cause oxidative harm (<xref ref-type="bibr" rid="ref74">Reczek and Chandel, 2015</xref>; <xref ref-type="bibr" rid="ref4">Azzi, 2022</xref>; <xref ref-type="bibr" rid="ref001">Sies, 2020</xref>; <xref ref-type="bibr" rid="ref11">Brand, 2016</xref>). Elevated ROS exposure can damage lipids, proteins, and DNA, resulting in cellular and mitochondrial dysfunction and reduced cell viability (<xref ref-type="bibr" rid="ref75">Redza-Dutordoir and Averill-Bates, 2016</xref>; <xref ref-type="bibr" rid="ref93">Thomas and Ashcroft, 2019</xref>; <xref ref-type="bibr" rid="ref85">Sies, 2015</xref>). The brain is particularly susceptible to oxidative stress due to its rich mitochondrial content (especially in neurons), high O<sub>2</sub> demands, limited damage repair capacity, and abundant polyunsaturated fatty acids (<xref ref-type="bibr" rid="ref65">Pearson-Smith and Patel, 2017</xref>). Oxidative stress is closely linked to neurodegenerative diseases, e.g., Parkinson&#x2019;s and Alzheimer&#x2019;s, as well as acute brain injuries stemming from prolonged seizures, strokes, and traumatic incidents (<xref ref-type="bibr" rid="ref65">Pearson-Smith and Patel, 2017</xref>; <xref ref-type="bibr" rid="ref108">Zhang et al., 2017</xref>; <xref ref-type="bibr" rid="ref8">Bhatti et al., 2018</xref>; <xref ref-type="bibr" rid="ref69">Puspita et al., 2017</xref>; <xref ref-type="bibr" rid="ref19">Cheignon et al., 2018</xref>). Mitochondria are an important source of endogenous ROS production, with the ETS being the site where ROS generation predominantly occurs (<xref ref-type="bibr" rid="ref96">Tirichen et al., 2021</xref>; <xref ref-type="bibr" rid="ref10">Brand, 2010</xref>). The superoxide anion (O<sub>2</sub><sup>&#x2022;-</sup>) is the most common ROS generated in mitochondria and is primarily produced at Complex I (CI) and Complex III (CIII) sites (<xref ref-type="bibr" rid="ref91">Tahara et al., 2009</xref>; <xref ref-type="bibr" rid="ref96">Tirichen et al., 2021</xref>). CI-derived O<sub>2</sub><sup>&#x2022;-</sup> enters the mitochondrial matrix and rapidly converts to hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), which can then be released into the cytosol. On the other hand, O<sub>2</sub><sup>&#x2022;-</sup> produced by CIII is primarily released into the intermembrane space, where it can either be converted into H<sub>2</sub>O<sub>2</sub> and then released into the cytosol, or it can traverse the mitochondrial outer membrane and transform into H<sub>2</sub>O<sub>2</sub> within the cytosol (<xref ref-type="bibr" rid="ref40">Hoehne et al., 2022</xref>; <xref ref-type="bibr" rid="ref9">Bleier et al., 2015</xref>; <xref ref-type="bibr" rid="ref58">Muller et al., 2004</xref>). O<sub>2</sub><sup>&#x2022;-</sup> originating from CI can also be produced via a process called reverse electron transfer (RET), which takes place when electrons return from ubiquinol to CI, reducing NAD<sup>+</sup> to NADH (<xref ref-type="bibr" rid="ref82">Scialo et al., 2017</xref>; <xref ref-type="bibr" rid="ref43">Koml&#x00F3;di et al., 2018a</xref>,<xref ref-type="bibr" rid="ref45">b</xref>). While both O<sub>2</sub><sup>&#x2022;-</sup> and H<sub>2</sub>O<sub>2</sub> serve as signaling molecules, H<sub>2</sub>O<sub>2</sub> is recognized as the primary ROS signaling molecule, and it can selectively oxidize target molecules at physiological concentrations (<xref ref-type="bibr" rid="ref89">Sinenko et al., 2021</xref>; <xref ref-type="bibr" rid="ref86">Sies and Jones, 2020</xref>).</p>
<p>O<sub>2</sub> levels have an impact on mitochondrial morphology, with mitochondria appearing tubular during tissue normoxia and fragmented during hypoxia (<xref ref-type="bibr" rid="ref49">Lee et al., 2020</xref>). The morphology of mitochondria varies according to their function and cellular requirements, and different physiological and pathophysiological conditions affect their shape (<xref ref-type="bibr" rid="ref95">Tilokani et al., 2018</xref>). Mitochondrial fission is vital for distributing mitochondria during cell division, apoptosis, intracellular transfer, and eliminating damaged mitochondria. In contrast, mitochondrial fusion enables the exchange of essential components, creating a more uniform network capable of rescuing compromised mitochondria (<xref ref-type="bibr" rid="ref104">Yapa et al., 2021</xref>; <xref ref-type="bibr" rid="ref101">Westermann, 2010</xref>). The process of mitochondrial fission is orchestrated by the GTPase dynamin-related protein 1 (DRP1). In contrast, mitochondrial fusion involves GTPases such as mitofusin 1 and 2 (MFN1/2) for fusion of the mitochondrial outer membrane and optic atrophy 1 (OPA1) for mitochondrial inner membrane fusion (<xref ref-type="bibr" rid="ref54">Macdonald et al., 2016</xref>; <xref ref-type="bibr" rid="ref2">Akepati et al., 2008</xref>). Interestingly, models of neurodegenerative diseases, e.g., Alzheimer&#x2019;s, Parkinson&#x2019;s, and epilepsy show changes in mitochondrial structure. For instance, Alzheimer&#x2019;s and Parkinson&#x2019;s disease models display increased mitochondrial fragmentation, while kainic acid epilepsy models exhibit mitochondrial swelling (<xref ref-type="bibr" rid="ref100">Wang et al., 2008</xref>; <xref ref-type="bibr" rid="ref47">Kudin et al., 2002</xref>; <xref ref-type="bibr" rid="ref103">Yang et al., 2021</xref>). Furthermore, owing to their distinctive cellular morphology, neurons require mitochondria to travel extended distances. Hypoxia can prompt the redistribution of mitochondria within cells, leading to their accumulation around the nucleus. This mitochondrial relocation is observed in both short- and long-term hypoxia and is believed to play a role in delivering mitochondrial ROS to the nucleus. These ROS trigger oxidative modifications in the promoter regions of genes under hypoxia-inducible factor 1 (HIF1) regulation, subsequently amplifying gene expression (<xref ref-type="bibr" rid="ref3">Al-Mehdi et al., 2012</xref>).</p>
<p>Diminished O<sub>2</sub> levels are detected through multiple pathways, with HIFs playing a vital role in maintaining O<sub>2</sub> balance by selectively controlling the expression of numerous genes in a tissue-specific manner (<xref ref-type="bibr" rid="ref51">Liu et al., 2021</xref>; <xref ref-type="bibr" rid="ref83">Semenza, 1999</xref>). HIFs govern a range of functions such as cell survival, proliferation, apoptosis, metabolism, energy production, and pro- and antioxidative responses (<xref ref-type="bibr" rid="ref62">Ostrowski and Zhang, 2020</xref>). Additionally, factors like mitochondrial ROS can activate the HIF pathway, even under normal O<sub>2</sub> conditions (<xref ref-type="bibr" rid="ref18">Chandel et al., 2000</xref>; <xref ref-type="bibr" rid="ref80">Sanjuan-Pla et al., 2005</xref>), a phenomenon referred to as pseudohypoxia (<xref ref-type="bibr" rid="ref41">Hou et al., 2014</xref>).</p>
<p>Hypoxia contributes to various neurological diseases, e.g., epilepsy, Parkinson&#x2019;s disease, and Alzheimer&#x2019;s disease and is a major cause of neurological disabilities and strokes (<xref ref-type="bibr" rid="ref14">Burtscher et al., 2021</xref>; <xref ref-type="bibr" rid="ref84">Shukitt-Hale et al., 1998</xref>; <xref ref-type="bibr" rid="ref87">Silva et al., 2016</xref>). Nevertheless, when exposed to mild oxygen deficiency, cells can undergo stress, triggering a response that offers protection or builds tolerance &#x2013; a phenomenon referred to as hypoxic preconditioning (HPC). The concept of HPC is that a mild and transient reduction in O<sub>2</sub> levels can prompt cellular defenses and enhance the ability to acclimate to varying O<sub>2</sub> conditions (<xref ref-type="bibr" rid="ref22">Dahl and Balfour, 1964</xref>; <xref ref-type="bibr" rid="ref90">Stetler et al., 2014</xref>). Many <italic>in vitro</italic> and <italic>in vivo</italic> studies demonstrate the neuroprotective attributes of HPC, with several factors suggested to contribute to the advantageous outcomes of HPC (<xref ref-type="bibr" rid="ref87">Silva et al., 2016</xref>; <xref ref-type="bibr" rid="ref106">Zhan et al., 2010</xref>; <xref ref-type="bibr" rid="ref94">Thompson et al., 2013</xref>; <xref ref-type="bibr" rid="ref63">Pan et al., 2014</xref>; <xref ref-type="bibr" rid="ref102">Yang et al., 2013</xref>; <xref ref-type="bibr" rid="ref107">Zhang et al., 2006</xref>; <xref ref-type="bibr" rid="ref98">Turovskaya et al., 2020</xref>; <xref ref-type="bibr" rid="ref109">Zhen et al., 2014</xref>). Preconditioning can manifest within two forms: rapid or delayed HPC. The former one occurs within minutes to hours, involving alterations in enzyme activity, protein phosphorylation, post-translational modifications, secondary messengers, ion channels, and expression of immediate early genes, whereas the latter one takes hours or days, ultimately leading to alterations in gene expression and the synthesis of new proteins (<xref ref-type="bibr" rid="ref107">Zhang et al., 2006</xref>; <xref ref-type="bibr" rid="ref98">Turovskaya et al., 2020</xref>; <xref ref-type="bibr" rid="ref50">Li et al., 2017</xref>; <xref ref-type="bibr" rid="ref5">Barone et al., 1998</xref>; <xref ref-type="bibr" rid="ref42">Kirino, 2002</xref>).</p>
<p>Epilepsy is a prevalent neurological condition known for its persistent susceptibility to spontaneous seizures, causing significant physical, psychological, social, and economic challenges for individuals and society (<xref ref-type="bibr" rid="ref28">Fisher et al., 2014</xref>). Although anti-seizure drugs (ASDs) are the primary epilepsy treatment, nearly 30% of patients cannot achieve seizure control (<xref ref-type="bibr" rid="ref20">Chen et al., 2018</xref>). Even those who respond to ASDs frequently still suffer from occasional seizures, encounter therapy side effects, and experience a gradual decline in functional abilities (<xref ref-type="bibr" rid="ref92">Thijs et al., 2019</xref>). As a result, researchers have delved into alternative therapies with neuroprotective potential to enhance clinical outcomes (<xref ref-type="bibr" rid="ref87">Silva et al., 2016</xref>; <xref ref-type="bibr" rid="ref109">Zhen et al., 2014</xref>; <xref ref-type="bibr" rid="ref21">Curia et al., 2014</xref>). Numerous studies have demonstrated the neuroprotective benefits of HPC, including its capacity to mitigate seizure susceptibility, frequency, and severity, as well as its role in diminishing neuronal loss and enhancing cognitive function (<xref ref-type="bibr" rid="ref32">Gao et al., 2014</xref>; <xref ref-type="bibr" rid="ref87">Silva et al., 2016</xref>; <xref ref-type="bibr" rid="ref98">Turovskaya et al., 2020</xref>; <xref ref-type="bibr" rid="ref102">Yang et al., 2013</xref>; <xref ref-type="bibr" rid="ref68">Pohle and Rauca, 1994</xref>; <xref ref-type="bibr" rid="ref31">Gao et al., 2012</xref>; <xref ref-type="bibr" rid="ref73">Rauca et al., 2000</xref>; <xref ref-type="bibr" rid="ref27">Emerson et al., 1999</xref>; <xref ref-type="bibr" rid="ref78">Rubaj et al., 2000</xref>; <xref ref-type="bibr" rid="ref107">Zhang et al., 2006</xref>).</p>
<p>The treatment options for epilepsy are not the only ones facing limitations. But the treatment of other neurodegenerative diseases, e.g., Alzheimer&#x2019;s and Parkinson&#x2019;s disease encounters constraints, underscoring the pressing need for the development of additional treatment options (<xref ref-type="bibr" rid="ref87">Silva et al., 2016</xref>; <xref ref-type="bibr" rid="ref92">Thijs et al., 2019</xref>; <xref ref-type="bibr" rid="ref66">Pereira, 2016</xref>; <xref ref-type="bibr" rid="ref53">Long et al., 2021</xref>). Despite its potential as a treatment approach for neurodegenerative diseases, the field of preconditioning still has remained understudied. Therefore, it is essential to delve deeper into the mechanisms that take place following HPC, as they may be accountable for adataption and tolerance, especially important in the brain, where neurons cannot regenerate (<xref ref-type="bibr" rid="ref79">Rybnikova and Samoilov, 2015</xref>; <xref ref-type="bibr" rid="ref90">Stetler et al., 2014</xref>). This study aimed to investigate and provide further insights into the biochemical changes induced by HPC, with a specific emphasis on mitochondria, the hub of O<sub>2</sub> consumption.</p>
<p>Initially, we evaluated the neuroprotective capacity of the HPC protocol employed by assessing the seizure threshold in an acute seizure mouse model. Next, we explored the impact of varying O<sub>2</sub> levels on mitochondrial respiration in brain tissue samples from both untreated and HPC-treated mice using high-resolution respirometry. Additionally, we examined alterations in mitochondrial respiration, ROS production and dynamics following mild hypoxia treatment in brain tissue samples. For this purpose, we created a Macro compatible with Fiji-ImageJ software, simplifying the analysis of mitochondrial morphology.</p>
<p>The results outlined in this study have already been made accessible online through LB&#x2019;s Ph.D. thesis (<xref ref-type="bibr" rid="ref7">Bergmeister, 2023</xref>).</p>
</sec>
<sec sec-type="materials|methods" id="sec2">
<label>2</label>
<title>Materials and methods</title>
<sec id="sec3">
<label>2.1</label>
<title>Animals</title>
<p>We used wild-type C57BL6/J male mice (aged 10&#x2013;25&#x202F;weeks). Mice were split into two groups: control (Ctrl) and HPC treated. They were housed under standard conditions (12/12 light/dark cycles, 23&#x202F;&#x00B0;C), with up to five mice per ventilated type II L cage, providing food and water <italic>ad libitum</italic>. Cages were enriched with bedding, nesting materials, and a mouse house. This study was approved by the Animal Ethics Committee of the Medical University Innsbruck and the Austrian Animal Experimentation Ethics Board (in accordance with EU Directive 2010/63/EU). We ensured that the number of mice utilized for the experiments was minimized to the greatest extent possible.</p>
</sec>
<sec id="sec4">
<label>2.2</label>
<title>Hypoxic preconditioning</title>
<p>Mice were subjected to a gas mixture consisting of 9% O<sub>2</sub> and 91% N<sub>2</sub> (Linde Gas) for 7&#x202F;h. For hypoxia treatment, up to 5 mice were placed in a new, airtight cage. These cages are equipped with air inlet and outlet valves, one valve was utilized to deliver the gas mixture, and the other one to monitor O<sub>2</sub> levels using an O<sub>2</sub> meter (Apogee Instruments). The measured O<sub>2</sub> concentration in the cages reached levels between 9 and 12% O<sub>2</sub>. The flow meter (Fyearfly) was set to maintain a flow rate of 2&#x2013;3&#x202F;L/min, refreshing air 15&#x2013;20 times per hour. Mice were monitored hourly during the 7-h hypoxia. <xref ref-type="fig" rid="fig1">Figure 1A</xref> illustrates the workflow of the present study. Immediately after hypoxia exposure (referred to as rapid HPC), samples were gathered for subsequent qPCR analyses (section 3.7) to evaluate the expression of genes linked to mitochondrial dynamics. Additionally, a further set of assessments was carried out 24&#x202F;h after the initiation of hypoxia (referred to as delayed HPC). These assessments encompassed the determination of seizure thresholds (section 3.3), measurement of mitochondrial respiration (section 3.5.1 and 3.5.2), evaluation of H<sub>2</sub>O<sub>2</sub> generation (section 3.5.2), and gene expression analyses (qPCR) targeting the same genes associated with mitochondrial dynamics.</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p>Experimental workflow and the influence of hypoxic preconditioning (HPC) on the seizure threshold. <bold>(A)</bold> In the <italic>in vivo</italic> part of the present study, C57BL6/J mice underwent 7&#x202F;h of hypoxia exposure (HPC). Immediately after hypoxia (rapid HPC), brain tissue samples were collected for qPCR analysis to assess the expression of key factors related to mitochondrial fusion and fission. Twenty-four hours after initiation of the hypoxic phase (17&#x202F;h after hypoxia, delayed HPC), the seizure threshold was measured and qPCR analyses were conducted to examine the expression of the same genes associated with mitochondrial fusion and fission. Moreover, mitochondrial respiration and ROS production were analyzed. Mitochondrial respiration was assessed under both air-saturated O<sub>2</sub> levels and conditions of intracellular tissue normoxia. For the <italic>in vitro</italic> part, CHO cells were subjected to 7&#x202F;h of hypoxia treatment. Immediately after hypoxia and 17&#x202F;h later, mitochondria were stained, the cells were fixed, and fluorescence microscopy analysis to evaluate mitochondrial morphology was performed. The image of the mouse featured in the upper section of the figure (<ext-link xlink:href="https://doi.org/10.5281/zenodo.6645614" ext-link-type="uri">https://doi.org/10.5281/zenodo.6645614</ext-link>) and the single cell displayed in the lower part of the figure (<ext-link xlink:href="https://doi.org/10.5281/zenodo.3926537" ext-link-type="uri">https://doi.org/10.5281/zenodo.3926537</ext-link>) were both obtained from SciDraw. <bold>(B)</bold> The seizure thresholds in naive and HPC-treated mice were determined by administering the GABA<sub>A</sub> receptor antagonist PTZ (pentylenetetrazole) until a seizure occurred. The seizure threshold was defined as the quantity of PTZ infused (mg) per kg of the mouse&#x2019;s body weight. The findings are expressed as the mean &#x00B1; SD. Statistical analysis was performed using a t-test, with the significance level set at &#x2264; 0.05.</p>
</caption>
<graphic xlink:href="fnmol-18-1628567-g001.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Diagram A illustrates the hypoxia protocol, showing analyses of mitochondrial dynamics and morphology immediately after hypoxia (Rapid HPC) and 17 h later (Delayed HPC), as well as measurements of seizure threshold, mitochondrial respiration, and ROS production at the delayed time point. Diagram B shows a bar graph comparing seizure thresholds in two groups, Ctrl and HPC, with HPC showing a significantly higher threshold.</alt-text>
</graphic>
</fig>
</sec>
<sec id="sec5">
<label>2.3</label>
<title>Seizure threshold</title>
<p>To test the neuroprotective potential of HPC we evaluated the seizure thresholds in both naive and HPC-treated mice (<italic>N</italic>&#x202F;=&#x202F;6/group), by applying the GABA<sub>A</sub> receptor antagonist pentylenetetrazole (PTZ). Following the measurement of body mass, mice were restrained for cannula insertion into the tail vein. Continual infusion of PTZ (10&#x202F;mg PTZ/mL 0.9% NaCl, pH 7.4) was performed in freely moving mice until inducing a tonic&#x2013;clonic seizure. The seizure threshold was determined based on the PTZ volume infused per kg of mouse. Infusion occurred at 100&#x202F;&#x03BC;L/min, with a maximum of 250&#x202F;&#x03BC;L administered. After mice experienced a generalized seizure, they were killed with a neck dislocation.</p>
</sec>
<sec id="sec6">
<label>2.4</label>
<title>Brain tissue preparation</title>
<p>Tissue preparation followed the protocol by <xref ref-type="bibr" rid="ref15">Burtscher et al. (2015)</xref> with some adjustments. Naive and HPC-treated mice (<italic>N</italic>&#x202F;=&#x202F;6&#x2013;15 mice) were killed through cervical dislocation. Brains were swiftly harvested, with dissections focusing on either the hippocampus, motor cortex, and striatum, or only the hippocampus and striatum. Samples from the hippocampus, motor cortex, and striatum were utilized for measurements of mitochondrial respiration under air-saturated O<sub>2</sub> levels (section 3.5.1) and gene expression analyses (section 3.7). However, due to constrained availability of O2k-FluoRespirometers (Oroboros Instruments), concurrent measurements of mitochondrial respiration and H<sub>2</sub>O<sub>2</sub> production under brain tissue normoxia (section 3.5.2) were carried out exclusively with the hippocampus and striatum. Brain tissues were immediately placed in an ice-cold mitochondrial respiration medium (MiR05Cr, 20&#x202F;mM creatine (Cr), without bovine serum albumin/BSA, Oroboros Instruments). After washing three times in MiR05Cr without BSA, tissues were quickly dried on blotting paper (GE Healthcare Life Science), weighed (Mettler Toledo AE 160), and approximately 6&#x202F;mg of wet tissue mass were suspended in 500&#x202F;&#x03BC;L of respiration medium. The remaining tissue was frozen (&#x2212;80&#x202F;&#x00B0;C) for qPCR analyses. Homogenization was conducted using a pre-cooled glass homogenizer (DWK Wheaton and tight fit; WiseStir homogenizer HS-30E, witeg Labortechnik GmbH) at 1000&#x202F;rpm with 10 strokes for the motor cortex and striatum, and 15 strokes for the hippocampus. We measured mitochondrial respiration and H<sub>2</sub>O<sub>2</sub> production of homogenates from 2&#x202F;mg of the wet tissue mass, suspended in mitochondrial respiration medium in air-calibrated 2&#x202F;mL Oroboros chambers (calibrated with MiR05Cr with BSA). Each measurement had two technical replicates. Post-measurement, samples were collected from each chamber and frozen (&#x2212;80&#x202F;&#x00B0;C) for later citrate synthase (CS) activity determination.</p>
</sec>
<sec id="sec7">
<label>2.5</label>
<title>High-resolution respirometry (HRR)</title>
<sec id="sec8">
<label>2.5.1</label>
<title>HRR at air-saturated O<sub>2</sub> concentrations</title>
<p>Mitochondrial function was evaluated using Oroboros FluoRespirometers (Oroboros Instruments, Innsbruck, Austria) and applying a Substrate-Uncoupler-Inhibitor Titration (SUIT) protocol. O<sub>2</sub> concentration [&#x03BC;M] and O<sub>2</sub> flux per tissue mass [pmol O<sub>2&#x00B7;</sub>s<sup>-1&#x00B7;</sup>mg<sup>&#x2212;1</sup>] were measured real-time using DatLab 7.4 software at 37&#x202F;&#x00B0;C near air-saturated O<sub>2</sub> conditions (150&#x2013;200&#x202F;&#x03BC;M, reoxygenations were performed by opening the Oroboros chambers). Samples from the hippocampus, motor cortex, and striatum were analyzed. The SUIT protocol utilized (<xref ref-type="fig" rid="fig2">Figure 2</xref>) followed the methodology outlined by <xref ref-type="bibr" rid="ref15">Burtscher et al. (2015)</xref> and <xref ref-type="bibr" rid="ref13">Burtscher et al. (2018)</xref> involving multiple steps to assess different respiratory states. The NADH (N)-linked LEAK state (N<italic><sub>L</sub></italic>) was initiated by introducing pyruvate (P; 5&#x202F;mM), malate (M, 2&#x202F;mM), and glutamate (G; 10&#x202F;mM). Activating the phosphorylation system, with kinetically saturating ADP concentrations (D; 2.5&#x202F;mM), enabled the assessment of OXPHOS through the N-linked pathway (N<italic><sub>P</sub></italic>). In the OXPHOS state, the CII-linked substrate succinate (S; 50&#x202F;mM) was employed to assess the convergent electron flow into the coenzyme Q through the NS pathway (NS<italic><sub>P</sub></italic>). The electron transfer (ET) capacity for the NS-linked pathway (NS<italic><sub>E</sub></italic>) was determined by CCCP (carbonyl cyanide m-chlorophenyl hydrazone) uncoupler titration (U; 1.5&#x2013;3.5&#x202F;&#x03BC;M). Careful titration of uncouplers was undertaken to identify optimal concentrations for maximal O<sub>2</sub> flux assessment. Further, the CI inhibitor rotenone (Rot; 0.5&#x202F;&#x03BC;M) was introduced to measure S-linked ET capacity (S<italic><sub>E</sub></italic>), and finally the CIII inhibitor antimycin A (Ama; 2.5&#x202F;&#x03BC;M) was used to quantify residual O<sub>2</sub> consumption (<italic>Rox</italic>). O<sub>2</sub> fluxes were corrected for <italic>Rox</italic> and normalized for wet tissue mass to determine the mass-specific O<sub>2</sub> flux. The activity of citrate synthase (CS [IU]) was used as a mitochondrial marker to express respiration as mitochondrial (mt)-specific O<sub>2</sub> flux (<xref ref-type="bibr" rid="ref15">Burtscher et al., 2015</xref>; <xref ref-type="bibr" rid="ref25">Doerrier et al., 2018</xref>; <xref ref-type="bibr" rid="ref35">Gnaiger, 2020</xref>; <xref ref-type="bibr" rid="ref36">Gnaiger et al., 2020</xref>).</p>
<fig position="float" id="fig2">
<label>Figure 2</label>
<caption>
<p>Mitochondrial respiration using a SUIT protocol (SUIT-028). Representative trace of mitochondrial respiration using a Substrate-Uncoupler-Inhibitor Titration (SUIT) protocol. The blue line represents O<sub>2</sub> concentration [&#x03BC;M], the red line O<sub>2</sub> flux per tissue wet mass [pmol<sub>&#x00B7;</sub>s<sup>&#x2212;1</sup><sub>&#x00B7;</sub>mg<sup>&#x2212;1</sup>]. The assessment of mitochondrial respiration was conducted using high-resolution respirometry (Oroboros FluoRespirometer), with data recorded using DatLab 7 software. Measurement was performed at O<sub>2</sub> levels near air saturation. 1PGM: Initial addition of pyruvate (P; 5&#x202F;mM), malate (M, 2&#x202F;mM), and glutamate (G; 10&#x202F;mM) to induce NADH- (N)-linked LEAK respiration N<italic><sub>L</sub></italic>. 2D: A kinetically saturating ADP concentration (D; 2.5&#x202F;mM) induced N-linked OXPHOS N<italic><sub>P</sub></italic>. 2<italic>c</italic>: Cytochrome <italic>c</italic> (c; 10&#x202F;&#x03BC;M) added to assess the integrity of the mitochondrial outer membrane<bold>. 3S</bold>: CII-substrate succinate (S; 50&#x202F;mM) added to evaluate NS-pathway OXPHOS capacity NS<italic><sub>P</sub></italic> (CI- and CII-linked). 4U: Stepwise titrations of the uncoupler carbonyl cyanide chlorophenylhydrazone CCCP (U; 1.5&#x2013;3.5&#x202F;&#x03BC;M) to reach maximum respiration as an estimate of NS-pathway ET capacity NS<italic><sub>E</sub></italic>. 5Rot: Inhibition of CI by rotenone (Rot; 0.5&#x202F;&#x03BC;M) to measure S-linked ET capacity S<italic><sub>E</sub></italic>. 6Ama: Inhibition of CIII by antimycin A (Ama; 2.5&#x202F;&#x03BC;M) to assess residual oxygen consumption <italic>Rox</italic> for baseline correction of O<sub>2</sub> flux in all mitochondrial respiratory states. The vertical bars for N<italic><sub>L</sub></italic> (red), N<italic><sub>P</sub></italic> and NS<italic><sub>P</sub></italic> (green), NS<italic><sub>E</sub></italic> and S<italic><sub>E</sub></italic> (blue) indicate the sections marked for calculation of respiratory flux. The shaded boxes provide a graphical explanation of the ratios (arrows): <italic>P</italic>-<italic>L</italic> control efficiency&#x202F;=&#x202F;(N<italic><sub>P</sub></italic>-N<italic><sub>L</sub></italic>)/N<italic><sub>P</sub></italic>&#x202F;=&#x202F;1-N<italic><sub>L</sub></italic>/N<italic><sub>P</sub></italic>; <italic>E</italic>-<italic>P</italic> control efficiency&#x202F;=&#x202F;(NS<italic><sub>E</sub></italic>-NS<italic><sub>P</sub></italic>)/NS<italic><sub>E</sub></italic>&#x202F;=&#x202F;1-NS<italic><sub>P</sub></italic>/NS<italic><sub>E</sub></italic>.</p>
</caption>
<graphic xlink:href="fnmol-18-1628567-g003.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Graph depicting oxygen concentration (&#x00B5;M) and flux per tissue mass (pmol/s/mg) over time in minutes. It includes segments labeled LEAK, OXPHOS, ET, and ROX with various sub-stages, such as NL, NP, and NSP, among others. Red, green and blue boxes represent different states and control efficiencies.</alt-text>
</graphic>
</fig>
<p>Flux control ratios (<italic>FCR</italic>s) were calculated by normalizing O<sub>2</sub> consumption in each state for the maximum O<sub>2</sub> flux (NS<italic><sub>E</sub></italic>), allowing for evaluation of mitochondrial respiratory control patterns irrespective of mitochondrial content. Additional control ratios were calculated (<xref ref-type="fig" rid="fig2">Figure 2B</xref>): <italic>E-P</italic> control efficiency and <italic>P-L</italic> control efficiency. <italic>E-P</italic> control efficiency (1-NS<italic><sub>P</sub></italic>/NS<italic><sub>E</sub></italic>) evaluates the limitation of OXPHOS capacity by the phosphorylation system. A value of 0 implies that OXPHOS capacity is not limited by the phosphorylation system (equal OXPHOS and ET capacities, <italic>P</italic>&#x202F;=&#x202F;<italic>E</italic>), while values above 0 indicate an increasing control over OXPHOS capacity by the phosphorylation system (OXPHOS capacity being lower than ET capacity, <italic>P</italic>&#x202F;&#x003C;&#x202F;<italic>E</italic>). <italic>P</italic>-<italic>L</italic> control efficiency (1-N<italic><sub>L</sub></italic>/N<italic><sub>P</sub></italic>) of 1 indicates a fully coupled system, while 0 indicates no coupling (<xref ref-type="bibr" rid="ref35">Gnaiger, 2020</xref>; <xref ref-type="bibr" rid="ref13">Burtscher et al., 2018</xref>; <xref ref-type="bibr" rid="ref15">Burtscher et al., 2015</xref>).</p>
</sec>
<sec id="sec9">
<label>2.5.2</label>
<title>HRR under physiologically relevant O<sub>2</sub> levels</title>
<p>Oroboros FluoRespirometer in combination with the green fluorescence sensors were used to study mitochondrial respiration and H<sub>2</sub>O<sub>2</sub> generation at physiologically relevant O<sub>2</sub> levels (30&#x2013;40&#x202F;&#x03BC;M, reoxygenations were performed by opening the Oroboros chambers). Homogenates from the hippocampus and striatum were analyzed. The SUIT protocol outlined in section 3.5.1 was implemented. O<sub>2</sub> concentration [&#x03BC;M], and O<sub>2</sub> and H<sub>2</sub>O<sub>2</sub> fluxes per tissue mass [pmol O<sub>2&#x00B7;</sub>s<sup>-1&#x00B7;</sup>mg<sup>&#x2212;1</sup>] and [pmol H<sub>2</sub>O<sub>2&#x00B7;</sub>s<sup>-1&#x00B7;</sup>mg<sup>&#x2212;1</sup>], respectively, were measured real-time using DatLab 7.4 software at 37&#x202F;&#x00B0;C. The Amplex&#x00AE; UltraRed (AmR) assay was used to measure the net production of H<sub>2</sub>O<sub>2</sub>, with emitted fluorescence correlating directly to the amount of H<sub>2</sub>O<sub>2</sub> converted to the fluorescent product UltroxRed (<xref ref-type="bibr" rid="ref44">Komlodi et al., 2021</xref>). The amperometric channel voltage was set to 500&#x202F;mV and the gain adjusted to 1,000. First, background H<sub>2</sub>O<sub>2</sub> calibration was carried out in the absence of biological sample to determine the chemical background fluorescence and AmR sensitivity. This calibration was performed by titrating H<sub>2</sub>O<sub>2</sub> in the presence of the chelator diethylenetriamine-<italic>N, N, N&#x2032;, N, N</italic>-pentaacetic acid (DTPA), superoxide dismutase (SOD), horseradish peroxidase (HRP), and AmR. Afterward, samples were added into the chambers. During the experiment, H<sub>2</sub>O<sub>2</sub> titration steps (0.1&#x202F;&#x03BC;M) were performed to monitor changes in fluorescence sensitivity over time. The H<sub>2</sub>O<sub>2</sub> calibration solution was prepared fresh every day (<xref ref-type="bibr" rid="ref43">Koml&#x00F3;di et al., 2018a</xref>,<xref ref-type="bibr" rid="ref45">b</xref>). At the beginning of the experiment, either H<sub>2</sub> or N<sub>2</sub> was introduced into the gas phase of the open chamber to lower the O<sub>2</sub> concentration, allowing the experiment to be performed at reduced O<sub>2</sub> levels. The traces presented in <xref ref-type="supplementary-material" rid="SM1">Supplementary Figures S1A,B</xref> show exemplary measurements of mitochondrial respiration and H<sub>2</sub>O<sub>2</sub> production.</p>
<p>O<sub>2</sub> fluxes were corrected and normalized as detailed in section 3.5.1. H<sub>2</sub>O<sub>2</sub> fluxes were corrected for background fluorescence and AmR sensitivity (<xref ref-type="bibr" rid="ref44">Komlodi et al., 2021</xref>). H<sub>2</sub>O<sub>2</sub> fluxes were normalized to the wet tissue mass and CS activity to determine mass-specific and mitochondria-specific H<sub>2</sub>O<sub>2</sub> flux. Additionally, the <italic>J</italic><sub>H2O2</sub>/<italic>J</italic><sub>O2</sub> ratio was calculated, representing H<sub>2</sub>O<sub>2</sub> produced per O<sub>2</sub> consumed.</p>
<p>Initially, tests were conducted to assess the influence of AmR and fluorescence light on mitochondrial respiration by comparing measurements in the presence/absence of AmR and fluorescence light. As changes were noted in mitochondrial respiration after hypoxia treatment due to AmR and fluorescence light presence (<xref ref-type="supplementary-material" rid="SM2">Supplementary Figures S2</xref>&#x2013;<xref ref-type="supplementary-material" rid="SM4">S4</xref>), separate measurements were taken for H<sub>2</sub>O<sub>2</sub> and O<sub>2</sub> fluxes from the same samples.</p>
</sec>
</sec>
<sec id="sec10">
<label>2.6</label>
<title>Citrate synthase (CS) activity</title>
<p>CS catalyzes the transformation of acetyl-CoA and oxaloacetate into citrate and CoA-SH:</p>
<p>Acetyl-CoA&#x202F;+&#x202F;oxaloacetate + H<sub>2</sub>O =&#x202F;&#x003E;&#x202F;citrate + CoA-SH.</p>
<p>The introduction of 5,5&#x2032;-dithiobis-2-nitrobenzoic acid (DTNB) initiates the irreversible formation of thionitrobenzoic acid (TNB, absorption at 412&#x202F;nm):</p>
<p>CoA-SH&#x202F;+&#x202F;DTNB =&#x202F;&#x003E;&#x202F;TNB&#x202F;+&#x202F;CoA-S-S-TNB.</p>
<p>CS activity was determined by mixing the following components in a glass cuvette: 0.31&#x202F;mM acetyl-CoA, 0.25% Triton X-100, 0.1&#x202F;mM DTNB, 50&#x202F;&#x03BC;L sample containing 2&#x202F;mg/mL wet tissue mass, and distilled deionized water. The reaction was initiated by adding 0.5&#x202F;mM oxalacetate. A glass cuvette containing distilled deionized water was used as blank. Acetyl-CoA was diluted in distilled deionized water, oxalacetate in 0.1&#x202F;M triethanolamine-HCl-buffer with 1&#x202F;mM EDTA (pH 8), and DTNB in Tris&#x2013;HCl-buffer (pH 8.1). The latter two solutions were freshly prepared daily. Using a spectrophotometer (Hitachi), the linear absorption increase at 412&#x202F;nm was measured every 10&#x202F;s for 120&#x202F;s. The change in absorption over time directly correlates with CS activity. Specific enzyme activity (<italic>v</italic>) was computed using the equation,</p>
<disp-formula id="E1"><mml:math id="M1"><mml:mi>v</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mi mathvariant="italic">rA</mml:mi><mml:mrow><mml:mi>l</mml:mi><mml:mo>&#x2217;</mml:mo><mml:msub><mml:mi>&#x03B5;</mml:mi><mml:mi mathvariant="normal">B</mml:mi></mml:msub><mml:mo>&#x2217;</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mi>B</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:mo>&#x2217;</mml:mo><mml:mfrac><mml:msub><mml:mi>V</mml:mi><mml:mtext mathvariant="italic">cuvette</mml:mtext></mml:msub><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mtext>sample</mml:mtext></mml:msub><mml:mo>&#x2217;</mml:mo><mml:mi>&#x03C1;</mml:mi></mml:mrow></mml:mfrac></mml:math></disp-formula>
<p><italic>v</italic> =&#x202F;specific activity per mg protein in international units (IU [&#x03BC;mol of citrate per min]).</p>
<p><italic>r<sub>A</sub></italic> =&#x202F;change of absorbance over time [min<sup>&#x2212;1</sup>].</p>
<p><italic>l</italic> =&#x202F;optical path length, 1&#x202F;cm.</p>
<p><italic>&#x03B5;</italic><sub>B</sub> =&#x202F;extinction coefficient of TNB (B) at 412&#x202F;nm and pH 8.1, 13.6&#x202F;mM<sup>&#x2212;1</sup>&#x00B7;cm<sup>&#x2212;1</sup>.</p>
<p><italic>v</italic><sub>B</sub> =&#x202F;stochiometric number of B (1).</p>
<p><italic>V</italic><sub>cuvette</sub> =&#x202F;cuvette volume, 1&#x202F;mL.</p>
<p><italic>V</italic><sub>sample</sub> =&#x202F;sample volume added, 50&#x202F;&#x03BC;L.</p>
<p><italic>&#x03C1;</italic> =&#x202F;sample mass concentration [mg<sub>&#x00B7;</sub>mL<sup>&#x2212;1</sup>] (<xref ref-type="bibr" rid="ref34">Gnaiger, 1993</xref>).</p>
</sec>
<sec id="sec11">
<label>2.7</label>
<title>Gene expression analysis</title>
<p>Tissue samples from the hippocampus, motor cortex, and striatum underwent gene expression analysis. Dynabeads&#x00AE; mRNA DIRECT&#x2122; Kit (Dynal) was used for mRNA extraction following the manufacturer&#x2019;s protocol. Purified mRNA (150&#x202F;ng) was utilized for first-strand cDNA synthesis with Jump StartTM REDTaq&#x00AE; ReadyMixTM Reaction Mix (Sigma). To determine the expression of target genes associated with mitochondrial dynamics (listed in <xref ref-type="table" rid="tab1">Table 1</xref>) real-time qPCR analyses were conducted using 1&#x202F;&#x03BC;L of generated cDNA plus specific primers (250&#x202F;nM of forward and reverse primers). As a master mix the 5x HOT FIREPol EvaGreen qPCR Mix Plus (Solis Biodyne) was used. Measurements were conducted using a Bio-Rad CFX Connect Real-Time System Thermal Cycler, and results were analyzed with Bio-Rad CFX Manager. The &#x0394;&#x0394;Ct method (2<sup>-&#x0394;&#x0394;Ct</sup>) was applied to normalize the target gene expression to the reference gene (<italic>Actb</italic>), enabling a comparison of gene expression levels across different groups.</p>
<table-wrap position="float" id="tab1">
<label>Table 1</label>
<caption>
<p>Target genes and primer sequences.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Gene</th>
<th align="left" valign="top">Marker for</th>
<th align="left" valign="top">Primer sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="2"><italic>mMfn1</italic></td>
<td align="left" valign="top" rowspan="2">Mitochondrial fusion</td>
<td align="left" valign="bottom">m<italic>Mfn1</italic> fwd CCGATGGAGATAAAGCCTACC</td>
</tr>
<tr>
<td align="left" valign="bottom">m<italic>Mfn1</italic> rev CAAGAGGGCACATTTTGCTT</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2"><italic>mMfn2</italic></td>
<td align="left" valign="top" rowspan="2">Mitochondrial fusion</td>
<td align="left" valign="bottom">m<italic>Mfn2</italic> fwd TCCCTCTCAAGCACTTTGT</td>
</tr>
<tr>
<td align="left" valign="bottom">m<italic>Mfn2</italic> rev CCAGTTCTGTGTTCCTGTGG</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2"><italic>mDrp1</italic></td>
<td align="left" valign="top" rowspan="2">Mitochondrial fission</td>
<td align="left" valign="bottom">m<italic>Drp1</italic> fwd CCAAAGTACCTGTAGGCGAT</td>
</tr>
<tr>
<td align="left" valign="bottom">m<italic>Drp1</italic> rev CAGCAGTGACGGCGAGGATA</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2"><italic>mOpa1</italic></td>
<td align="left" valign="top" rowspan="2">Mitochondrial fusion</td>
<td align="left" valign="bottom">m<italic>Opa1</italic> fwd CTATAAGTGGATTGTGCCTGA</td>
</tr>
<tr>
<td align="left" valign="bottom">m<italic>Opa1</italic> rev GCAATCATTTCCAGCACACTG</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2"><italic>mActb</italic></td>
<td align="left" valign="top" rowspan="2">Housekeeping gene</td>
<td align="left" valign="bottom">m<italic>Actb</italic> fwd CATTGCTGACAGGATGCAGAAGG</td>
</tr>
<tr>
<td align="left" valign="bottom">m<italic>Actb</italic> rev TGCTGGAAGGTGGACAGTGAGG</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>All primers were purchased from Microsynth; fwd, forward; rev, reverse.</p>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec12">
<label>2.8</label>
<title>Staining of mitochondria in cell culture</title>
<p>Mitochondrial staining was conducted using CHO cells, comparing Ctrl cells to those exposed to 7&#x202F;h of hypoxia. The stained cells were either fixed immediately after hypoxia treatment (rapid HPC) or 17&#x202F;h later (delayed HPC). Cells were cultivated in DMEM/F-12 medium supplemented with fetal bovine serum (FBS; 10%), glutamax (1x), penicillin and streptomycin (100&#x202F;U/mL), and G418 (400&#x202F;&#x03BC;g/mL) at 37&#x202F;&#x00B0;C and 5% CO<sub>2</sub>. Mitochondrial staining was conducted using 1&#x202F;mM MitoTracker Red CMXRos dye dissolved in DMSO.</p>
<p>The day prior to the experiment, a total of 10<sup>6</sup> cells were seeded in 10&#x202F;cm<sup>2</sup> dishes containing cover slips. To induce hypoxia, the cells were positioned in a hypoxia incubator chamber (Billups-Rothenberg Inc.), where the gas mixture (9% O<sub>2</sub>, 5% CO<sub>2</sub>, and 86% N<sub>2</sub>; Linde Gas) was introduced. Following this, the hypoxia chamber containing the cells was transferred into the incubator (Thermo Fisher Scientific) and maintained for a duration of 7&#x202F;h. Hourly, measurements of the O<sub>2</sub> concentration were made, and the gas mixture was refreshed.</p>
<p>To prepare for staining, both Ctrl and treated cells were rinsed with PBS, and then a colorless medium (DMEM medium without BSA and phenol red) was added. Subsequently, 1&#x202F;&#x03BC;L of the 1&#x202F;mM MitoTracker Red CMXRos stock solution was added and incubated for 45&#x202F;min at 37&#x202F;&#x00B0;C in the dark. Afterward, cells were washed twice with PBS and then fixed for 20&#x202F;min at room temperature in the dark with a solution composed of paraformaldehyde (PFA, 3%) and glutaraldehyde (GA, 1.5%) dissolved in PBS at a pH of 7.4 (<xref ref-type="bibr" rid="ref70">Qin et al., 2021</xref>). After fixation, cells were washed three additional times in PBS and the coverslips were mounted onto microscope slides by using Vectashield mounting medium.</p>
<p>Images were captured using a fluorescence microscope (Zeiss; 63 x objective, 10 x magnification in camera tube) utilizing immersion oil. These images were subjected to analysis using Fiji-ImageJ software. In order to ensure unbiased assessment, samples were blinded for both microscopy analysis and subsequent evaluation. Four cover slips per condition were analyzed, from which three cells were chosen at random per cover slip. The average value derived from these three cells was employed for subsequent analysis. Mitochondria were automatically identified through a Macro we developed, as demonstrated in <xref ref-type="fig" rid="fig3">Figure 3B</xref>. This Macro improved contrast, established a threshold for positive signals (mitochondria), and eliminated background noise. However, the Macro had limitations, necessitating manual correction for false positives. Subsequently, the cell of interest was delineated, and particle number and size (area) were quantified. To further minimize the risk of false positives, particles equal to or smaller than an area of 3 (arbitrary unit) were excluded. Cell size, derived from the unmodified image, was used for normalization purposes. For each condition, the average mitochondrial size per cell, along with the quantity of mitochondrial count per cell area and mitochondrial area per cell area, was determined.</p>
<fig position="float" id="fig3">
<label>Figure 3</label>
<caption>
<p>Effect of HPC-treatment on mitochondrial morphology <italic>in vitro</italic>. <bold>(A)</bold> Fluorescence microscopy images showcasing mitochondria stained with MitoTracker Red CMXRos in CHO cells, provided as representative examples. One million cells were cultured one day before the experiment. On the subsequent day, the Ctrl cells were left untreated, while the HPC cells underwent a 7-h hypoxia treatment. Afterward, mitochondria were stained, and cells were fixed. For the rapid HPC group, staining and fixation occurred immediately after hypoxia, while the delayed HPC group underwent these processes 17&#x202F;h later. Imaging was conducted using a fluorescence microscope with a 63x resolution and immersion oil. <bold>(B)</bold> Figures illustrating the evaluation process of stained mitochondria in CHO cells. The evaluation was conducted utilizing Fiji-ImageJ, which included applying a Macro to improve contrast and define a threshold for detecting positive signals. False positives were manually removed. Following that, the cell of interest was encircled and examined to determine the quantity of particles (first column) and their corresponding areas (second column). Furthermore, the original image (first image) was employed to assess cell size. <bold>(C)</bold> The average mitochondrial area (size), mitochondrial number, and total mitochondrial area per cell were determined. To account for differences in cell sizes, the mitochondrial count and total mitochondrial area were adjusted relative to the cell&#x2019;s size. The total mitochondrial area relative to cell area is expressed as a percentage. Data represented as means &#x00B1; SD. We conducted a one-way ANOVA test with a significance threshold set at &#x2264; 0.05.</p>
</caption>
<graphic xlink:href="fnmol-18-1628567-g002.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Panel A shows fluorescence microscopy images of cells under three conditions: control, rapid HPC, and delayed HPC. Panel B displays image processing steps, illustrating cellular structures analyzed. Panel C presents bar graphs comparing mean mitochondrial area, mitochondrial count per cell area, and total mitochondrial area per cell area across the conditions, with p-values indicated.</alt-text>
</graphic>
</fig>
</sec>
<sec id="sec13">
<label>2.9</label>
<title>Summary of the data</title>
<p>In order to offer a comprehensive perspective on the influence of HPC throughout the entire brain, we aggregated the data collected from the assessed brain regions. The mean value from combined individual brain regions was utilized for conducting statistical analysis. Furthermore, specific data from individual brain regions can be found in the <xref ref-type="sec" rid="sec38">Supplementary materials</xref>.</p>
</sec>
<sec id="sec14">
<label>2.10</label>
<title>Statistical analyses</title>
<p>Statistical analyses were performed using GraphPad Prism 9 software. Prior to evaluating statistical significance, the ROUT method was employed to identify outliers. Comparative analyses were conducted between two groups, Ctrl and HPC-treated mice, for seizure threshold, mitochondrial respiration, and H<sub>2</sub>O<sub>2</sub> production. To evaluate the seizure threshold a <italic>t-</italic>test was utilized to compare means between the groups. A <italic>p</italic>-value of &#x2264; 0.05 was considered statistically significant, and results are presented as mean &#x00B1; standard deviation (SD).</p>
<p>For both mitochondrial respiration and H<sub>2</sub>O<sub>2</sub> production we employ nonparametric tests. The Mann&#x2013;Whitney U test was used to compare group medians, with significance defined at &#x2264; 0.05. Results are expressed as median &#x00B1; interquartile range (IQR).</p>
<p>The evaluation of mitochondrial dynamics encompassed three groups: Ctrl, rapid HPC, and delayed HPC. A one-way analysis of variance (ANOVA) test was administered to compare the means among the groups. Statistically significant results were considered with a <italic>p</italic>-value of &#x2264; 0.05, and findings are reported as mean &#x00B1; SD. Additionally, the &#x0160;id&#x00E1;k multiple comparisons test was applied to correct for multiple comparisons.</p>
</sec>
</sec>
<sec sec-type="results" id="sec15">
<label>3</label>
<title>Results</title>
<sec id="sec16">
<label>3.1</label>
<title>Increased seizure threshold after HPC</title>
<p>To assess the neuroprotective capabilities of the HPC protocol, we examined seizure thresholds in both naive mice (N&#x202F;=&#x202F;6) and those subjected to HPC treatment (<italic>N</italic>&#x202F;=&#x202F;6) by applying the GABA<sub>A</sub> receptor antagonist, PTZ. As depicted in <xref ref-type="fig" rid="fig1">Figure 1B</xref>, HPC treatment significantly elevated the seizure threshold in C57BL6/J mice.</p>
</sec>
<sec id="sec17">
<label>3.2</label>
<title>Mitochondrial respiration and H<sub>2</sub>O<sub>2</sub> production</title>
<sec id="sec18">
<label>3.2.1</label>
<title>Mitochondrial respiration under conditions of air-saturated O<sub>2</sub> concentrations</title>
<p>Using high-resolution respirometry, we analyzed mitochondrial respiration across various respiratory states (<xref ref-type="fig" rid="fig2">Figure 2</xref>). In order to investigate the impact of different O<sub>2</sub> levels on mitochondrial respiration, experiments were conducted near air saturation (150&#x2013;200&#x202F;&#x03BC;M O<sub>2</sub>) and O<sub>2</sub> levels close to physiological intracellular tissue normoxia (30&#x2013;40&#x202F;&#x03BC;M) for brain tissue cells (<xref ref-type="bibr" rid="ref39">Hadanny and Efrati, 2020</xref>). The pooled data, combining results for hippocampus, motor cortex, and striatum, on mitochondrial respiration near air-saturated O<sub>2</sub> conditions are displayed in <xref ref-type="fig" rid="fig4">Figure 4</xref>. <xref ref-type="supplementary-material" rid="SM5">Supplementary Figures S5</xref>, <xref ref-type="supplementary-material" rid="SM6">S6</xref> show the detailed unpooled data. For mass-specific O<sub>2</sub> flux and <italic>FCR</italic> 15 controls (including controls from experiments with rapid HPC treated mice) and 7 delayed HPC treated mice were analysed. For citrate synthase specific O<sub>2</sub> flux 7 controls and 5 HPC treated mice were analysed. In the <italic>E</italic>-<italic>P</italic> control efficacy, the N-linked <italic>FCR</italic>, the NS-linked <italic>FCR</italic>, S-linked ET <italic>FCR</italic> 1 HPC treated mouse was identified as outlier and excluded from analysis.</p>
<fig position="float" id="fig4">
<label>Figure 4</label>
<caption>
<p>Effect of HPC-treatment on mitochondrial respiration measured near air-saturated O<sub>2</sub> concentrations. Means of pooled data from hippocampus, motor cortex, and striatum. Mass-specific O<sub>2</sub> flux [pmol<sub>&#x00B7;</sub>s<sup>&#x2212;1</sup><sub>&#x00B7;</sub>mg<sup>&#x2212;1</sup>] was normalized for wet tissue mass. Citrates synthase activity (CS [IU]) was used as a mitochondrial marker for expression of mt-specific O<sub>2</sub> flux [pmol<sub>&#x00B7;</sub>s<sup>&#x2212;1</sup><sub>&#x00B7;</sub>IU <sup>&#x2212;1</sup>]. Flux control ratios <italic>FCR</italic> were normalized for maximal O<sub>2</sub> flux NS<italic><sub>E</sub></italic>. <bold>(A)</bold> NADH-linked LEAK respiration N<italic><sub>L</sub></italic>. <bold>(B)</bold> NADH-linked OXPHOS capacity N<italic><sub>P</sub></italic>. <bold>(C)</bold> NADH- &#x0026; succinate-linked OXPHOS capacity NS<italic><sub>P</sub></italic>. <bold>(D)</bold> NADH- &#x0026; succinate-linked ET capacity NS<italic><sub>E</sub></italic>. <bold>(E)</bold> Succinate-linked ET capacity S<italic><sub>E</sub></italic>. <bold>(F)</bold> Respirometric control efficiencies. See figure legend 2 for respiratory states and rates, and for definition of respirometric control efficiencies. Data represent medians &#x00B1; IQR and statistical significance was determined using the Mann&#x2013;Whitney U test, with the significance level set at &#x2264; 0.05. For mass-specific O<sub>2</sub> flux and <italic>FCR</italic> 15 controls and 7 HPC treated mice were analysed. For CS-specific O<sub>2</sub> flux 7 controls and 5 HPC treated mice were analysed. In the <italic>E</italic>-<italic>P</italic> control efficacy, the N-linked <italic>FCR</italic>, the NS-linked <italic>FCR</italic>, S-linked ET <italic>FCR</italic> 1 HPC treated mouse was identified as outlier and excluded from analysis.</p>
</caption>
<graphic xlink:href="fnmol-18-1628567-g004.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Bar charts compare control (Ctrl) and hypoxic preconditioning (HPC) treated groups for oxygen flux and flux control ratios (FCR) during various mitochondrial states: N-linked LEAK, N-linked OXPHOS, NS-linked OXPHOS, NS-linked ET, and S-linked ET. Additional charts show E-P and P-L control efficiency. Each bar includes standard deviations and p-values indicating statistical significance.</alt-text>
</graphic>
</fig>
<p>Citrate synthase activity was used as a matrix marker enzyme, and NS-linked ET capacity served as an internal functional marker to calculate flux control ratios. Under near air-saturated O<sub>2</sub> levels post HPC treatment, N-linked LEAK respiration was significantly reduced in mass-specific and CS-specific O<sub>2</sub> flux, as well as in the <italic>FCR</italic> (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), when compared to the Ctrl group. Moreover, following HPC treatment, we noted a reduction in CS-specific O<sub>2</sub> flux during N- and NS-linked OXPHOS (<xref ref-type="fig" rid="fig4">Figures 4B</xref>,<xref ref-type="fig" rid="fig4">C</xref>), alongside a decline in NS-linked ET capacity (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Nevertheless, there were no alterations in mass-specific O<sub>2</sub> flux and in the <italic>FCR</italic> observed between the two groups (N- and NS-linked OXPHOS and NS-linked ET capacity). Furthermore, in comparison to Ctrl mice, HPC led to reductions in both mass-specific and CS-specific O<sub>2</sub> flux, along with a diminished <italic>FCR</italic> of S-linked ET capacity (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). <italic>E-P</italic> and <italic>P-L</italic> control efficiencies did not exhibit significant changes due to HPC (<xref ref-type="fig" rid="fig4">Figure 4F</xref>).</p>
</sec>
<sec id="sec19">
<label>3.2.2</label>
<title>Increased N-linked LEAK respiration after HPC under intracellular tissue normoxia</title>
<p>The findings from the analysis of mitochondrial respiration performed under physiologically relevant O<sub>2</sub> levels are illustrated in <xref ref-type="fig" rid="fig5">Figure 5</xref>. The results presented here represent pooled data, combining results for hippocampus and striatum. Eight control and 6 HPC treated mice were analysed throughout. For NS-linked <italic>FCR</italic> and <italic>P-L</italic> control efficiency one HPC treated mouse was identified and excluded from analysis. Unpooled data are available in <xref ref-type="supplementary-material" rid="SM7">Supplementary Figures S7</xref>, <xref ref-type="supplementary-material" rid="SM8">S8</xref>. In contrast to the outcomes observed near air-saturated O<sub>2</sub> conditions, HPC induced significant elevations in mass-specific O<sub>2</sub> fluxes, CS-specific O<sub>2</sub> flux, and the <italic>FCR</italic> of N-linked LEAK when compared to the Ctrl (<xref ref-type="fig" rid="fig5">Figure 5A</xref>).</p>
<fig position="float" id="fig5">
<label>Figure 5</label>
<caption>
<p>Effect of HPC-treatment on mitochondrial respiration assessed under tissue normoxia at O<sub>2</sub> concentration of 30&#x2013;40&#x202F;&#x03BC;M. Means of pooled data for hippocampus and striatum. <bold>(A)</bold> NADH-linked LEAK respiration N<italic><sub>L</sub></italic>. <bold>(B)</bold> NADH-linked OXPHOS capacity N<italic><sub>P</sub></italic>. <bold>(C)</bold> NADH- &#x0026; succinate-linked OXPHOS capacity NS<italic><sub>P</sub></italic>. <bold>(D)</bold> NADH- &#x0026; succinate-linked ET capacity NS<italic><sub>E</sub></italic>. <bold>(E)</bold> Succinate-linked ET capacity S<italic><sub>E</sub></italic>. <bold>(F)</bold> Respirometric control efficiencies. See figure legend 2 for respiratory states and rates, and for definition of respirometric control efficiencies, and figure legend 3 for normalization of O<sub>2</sub> flux. Data represent medians &#x00B1; IQR and statistical significance was determined using the Mann&#x2013;Whitney U test, with a threshold of &#x2264; 0.05 considered statistically significant. Eight control and 6 HPC treated mice were analysed throughout. For NS-linked <italic>FCR</italic> and <italic>P-L</italic> control efficiency one HPC treated mouse was identified and excluded from analysis.</p>
</caption>
<graphic xlink:href="fnmol-18-1628567-g005.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Several bar graphs compare oxygen flux and control efficiency between control (Ctrl) and hypoxic preconditioning (HPC) treated groups across different experimental conditions. Panels A to E present mass-specific and mitochondrial-specific oxygen flux for N-linked LEAK, N-linked OXPHOS, NS-linked OXPHOS, NS-linked ET, and S-linked ET. Panel F shows E-P and P-L control efficiencies. The graphs depict Ctrl in light green and HPC in dark green. Statistical significance is indicated on select comparisons.</alt-text>
</graphic>
</fig>
<p>Furthermore, diverging from the results obtained near air-saturated O<sub>2</sub> conditions, HPC treatment led to a significant increase in both mass-specific and CS-specific O<sub>2</sub> flux during N- and NS-linked OXPHOS (<xref ref-type="fig" rid="fig5">Figures 5B</xref>,<xref ref-type="fig" rid="fig5">C</xref>), as well as N- and NS-linked ET capacity (<xref ref-type="fig" rid="fig5">Figures 5D</xref>,<xref ref-type="fig" rid="fig5">E</xref>) when compared to the Ctrl. The <italic>FCR</italic>s of these states remained unaffected by these changes.</p>
<p>The <italic>E</italic>-<italic>P</italic> control efficiency remained unaltered by HPC treatment. However, there was a significant decrease in <italic>P</italic>-<italic>L</italic> control efficiency within the HPC-treated group (<xref ref-type="fig" rid="fig5">Figure 5F</xref>).</p>
</sec>
<sec id="sec20">
<label>3.2.3</label>
<title>HPC treatment increased H<sub>2</sub>O<sub>2</sub> production during N-linked LEAK and OXPHOS</title>
<p>H<sub>2</sub>O<sub>2</sub> flux was measured under intracellular tissue normoxia (<xref ref-type="supplementary-material" rid="SM1">Supplementary Figure S1</xref>). The pooled results of ROS production measurements, combining results for hippocampus and striatum, are depicted in <xref ref-type="fig" rid="fig6">Figure 6</xref> (unpooled data are available in <xref ref-type="supplementary-material" rid="SM9">Supplementary Figures S9</xref>, <xref ref-type="supplementary-material" rid="SM10">S10</xref>). 8 control and 6 HPC treated mice were analysed throughout. For N-linked mt-specific H<sub>2</sub>O<sub>2</sub> flux one HPC treated mouse was identified and excluded from analysis. Following HPC, a significant increase in CS-specific H<sub>2</sub>O<sub>2</sub> flux during LEAK respiration in the N-linked pathway was observed. However, HPC did not yield significant changes in LEAK respiration for either the mass-specific H<sub>2</sub>O<sub>2</sub> flux or the ratio of H<sub>2</sub>O<sub>2</sub> production to O<sub>2</sub> consumption (<italic>J</italic><sub>H2O2</sub>/<italic>J</italic><sub>O2</sub>). Furthermore, significant elevations were observed after HPC in both mass-specific and CS-specific H<sub>2</sub>O<sub>2</sub> fluxes, along with the <italic>J</italic><sub>H2O2</sub>/<italic>J</italic><sub>O2</sub> ratio, during N-linked OXPHOS (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Conversely, H<sub>2</sub>O<sub>2</sub> production during NS-linked OXPHOS (<xref ref-type="fig" rid="fig6">Figure 6C</xref>) and N- and NS-linked ET capacity (<xref ref-type="fig" rid="fig6">Figures 6D</xref>,<xref ref-type="fig" rid="fig6">E</xref>) displayed no significant changes. The application of Ama enabled the assessment of the maximum contribution of CIII to H<sub>2</sub>O<sub>2</sub> production (<xref ref-type="bibr" rid="ref61">Olowe et al., 2020</xref>). Mass-specific H<sub>2</sub>O<sub>2</sub> production and <italic>J</italic><sub>H2O2</sub>/<italic>J</italic><sub>O2</sub> significantly decreased following HPC, with no significant alteration in CS-specific H<sub>2</sub>O<sub>2</sub> production.</p>
<fig position="float" id="fig6">
<label>Figure 6</label>
<caption>
<p>Effect of HPC-treatment on H<sub>2</sub>O<sub>2</sub> production under tissue normoxia at O<sub>2</sub> concentration of 30&#x2013;40&#x202F;&#x03BC;M. Means of pooled data for hippocampus and striatum. Net H<sub>2</sub>O<sub>2</sub> flux measured in the following states: <bold>(A)</bold> NADH-linked LEAK N<italic><sub>L</sub></italic>. <bold>(B)</bold> NADH-linked OXPHOS N<italic><sub>P</sub></italic>. <bold>(C)</bold> NADH- &#x0026; succinate-linked OXPHOS NS<italic><sub>P</sub></italic>. <bold>(D)</bold> NADH- &#x0026; succinate-linked ET NS<italic><sub>E</sub></italic>. <bold>(E)</bold> Succinate-linked ET S<italic><sub>E</sub></italic>. <bold>(F)</bold> Maximal contribution of CIII to H<sub>2</sub>O<sub>2</sub> production after adding the CIII inhibitor antimycin A. The <italic>J</italic><sub>H2O2</sub>/<italic>J</italic><sub>O2</sub> ratio is the proportion of H<sub>2</sub>O<sub>2</sub> produced to O<sub>2</sub> consumed. H<sub>2</sub>O<sub>2</sub> flux was normalized to O<sub>2</sub> flux in the absence of AmR. See figure legend 2 for respiratory states and rates, and figure legend 3 for normalization of flux. Data represent medians &#x00B1; IQR. Statistical test: Mann&#x2013;Whitney U test, &#x2264; 0.05, was defined as statistically significant. Eight control and 6 HPC treated mice were analysed throughout. For N-linked mt-specific H<sub>2</sub>O<sub>2</sub> flux one HPC treated mouse was identified and excluded from analysis.</p>
</caption>
<graphic xlink:href="fnmol-18-1628567-g006.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Bar graphs showing hydrogen peroxide flux in various states: A) N-linked LEAK, B) N-linked OXPHOS, C) NS-linked OXPHOS, D) NS-linked ET, E) S-linked ET, and F) CIII contribution. Three graphs per state compare mass-specific and mitochondrial-specific flux, and the ratio of hydrogen peroxide flux to oxygen flux, between control (Ctrl) and hypoxic preconditioning (HPC) treated groups. Statistical significance is indicated above each comparison.</alt-text>
</graphic>
</fig>
</sec>
</sec>
<sec id="sec21">
<label>3.3</label>
<title>Mitochondrial fusion and fission</title>
<sec id="sec22">
<label>3.3.1</label>
<title>Changes in mRNA expression</title>
<p>Real-time qPCR analyses were employed to assess the expression of mitochondrial fusion and fission factors. The outcomes, presented in <xref ref-type="fig" rid="fig7">Figure 7</xref>, represent pooled data, combining results for hippocampus, motor cortex, and striatum. <xref ref-type="supplementary-material" rid="SM11">Supplementary Figure S11</xref> provides an overview of the mRNA expression in individual brain regions. Fifteen control and 6 rapid HPC and 8 delayed HPC treated mice were analysed. As for both treatment groups control animals were included in each analytical run, the N of controls is higher than the N in the treatment groups. For <italic>Mfn2</italic> one control and one rapid HPC treated mouse was identified and excluded from analysis. For <italic>Opa 1</italic> one rapid HPC and one delayed HPC treated mouse was identified and excluded from analysis.</p>
<fig position="float" id="fig7">
<label>Figure 7</label>
<caption>
<p>Effect of rapid and delayed HPC-treatment on mRNA expression levels of critical mitochondrial fusion <bold>(A)</bold> and fission <bold>(B)</bold> factors. Real-time qPCR analysis was used to assess the mRNA expression levels of specific target genes, such as fusion factors <italic>Mf1</italic>, <italic>Mfn2</italic>, and <italic>Opa1</italic>, as well as the fission factor <italic>Drp1</italic>. Three distinct mouse groups were examined: untreated (Ctrl), immediately after hypoxia (rapid HPC), and 17&#x202F;h after hypoxia (delayed HPC). The expression levels were normalized to a housekeeping gene (<italic>Actb</italic>) and are reported as fold changes relative to the Ctrl group. Data represent means &#x00B1; SD, and statistical significance was determined through one-way ANOVA, with a significance threshold of &#x2264; 0.05. 15 control and 6 rapid HPC and 8 HPC treated mice were analysed. For <italic>Mfn2</italic> one control and one rapid HPC treated mouse was identified and excluded from analysis. For <italic>Opa 1</italic> one rapid HPC and one delayed HPC treated mouse was identified and excluded from analysis.</p>
</caption>
<graphic xlink:href="fnmol-18-1628567-g007.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Bar graphs displaying fold change in mRNA expression of mitochondrial fusion and fission factors. Panel A shows Mfn1, Mfn2, and Opa1 involved in mitochondrial fusion with significant changes in rapid and delayed HPC compared to control. Panel B shows Drp1 related to mitochondrial fission, with minimal change across conditions. Statistical significance is indicated with p-values.</alt-text>
</graphic>
</fig>
<p>Subsequent to hypoxia treatment (rapid HPC group), a significant upregulation in the expression of mitochondrial fusion factors (<italic>Mfn1</italic>, <italic>Mfn2</italic>, and <italic>Opa1</italic>) was noted. However, after a 17-h interval (delayed HPC group), the expression levels of <italic>Mfn1</italic> and <italic>Mfn2</italic> exhibited no significant differences compared to control levels; conversely, these levels were significantly reduced in comparison to the rapid HPC group. Meanwhile, <italic>Opa1</italic> expression also displayed a significant increase in the delayed HPC group compared to the Ctrl group.</p>
<p>While the expression of the fission factor <italic>Drp1</italic> did not exhibit significant changes between the groups overall, a closer examination of individual expression levels revealed a significant reduction in <italic>Drp1</italic> expression immediately after hypoxia in hippocampal and motor cortical tissue, although such reduction was not observed in striatal tissue (<xref ref-type="supplementary-material" rid="SM11">Supplementary Figure S11</xref>). The expression of the reference gene beta-actin was not changed under the mild hypoxic conditions. Ct values were 19.99&#x202F;&#x00B1; 0,71 (<italic>N</italic> =&#x202F;41) for na&#x00EF;ve mice; 20,27 &#x00B1; 0,82 (<italic>N</italic> =&#x202F;21) for the delayed HPC group and 20,01 &#x00B1; 0,63 (<italic>N</italic> =&#x202F;13) for the immediately analyzed group.</p>
</sec>
<sec id="sec23">
<label>3.3.2</label>
<title>Microscopy analysis</title>
<p>To gain a first impression of morphological changes induced by HPC we exposed CHO cells to HPC. Cultured cells in a monolayer provide a much cleared picture of mitochondrial morphology than the complex situation in slices from mouse brain. Fluorescence microscopy was employed to capture images of stained mitochondria in CHO cells, as illustrated in <xref ref-type="fig" rid="fig3">Figure 3A</xref>. Notably, in the rapid HPC group, mitochondria exhibited heightened fusion, resulting in elongated interconnected structures compared to Ctrl conditions. While some mitochondria in the delayed HPC group displayed an increase in fusion, most of them exhibited a Ctrl-like phenotype. The analyses of the images (<xref ref-type="fig" rid="fig3">Figure 3C</xref>) indicate a significant rise in the mean mitochondrial area and a significant reduction in the number of mitochondria per cell area immediately after hypoxia. In contrast, the delayed HPC group exhibited no differences compared to the Ctrl group concerning both the mean mitochondrial area and the number of mitochondria per cell area. Additionally, the total mitochondrial area per cell area remained unaffected by the hypoxia treatment across the tested groups.</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion" id="sec24">
<label>4</label>
<title>Discussion</title>
<p>Hypoxia, characterized by an insufficient O<sub>2</sub> supply to tissues, poses a substantial threat to the central nervous system. The brain, heavily reliant on O<sub>2</sub> for its energy demands, is particularly susceptible to hypoxic challenges (<xref ref-type="bibr" rid="ref17">Carreau et al., 2011</xref>). Nonetheless, depending on the duration and intensity of hypoxia, cells have the capacity to adapt, experience damage, or undergo cell death (<xref ref-type="bibr" rid="ref81">Schonenberger and Kovacs, 2015</xref>), underscoring the importance of controlled hypoxia in determining the outcome. Mild oxygen deficiency has the potential to induce cellular stress, culminating in a protective or tolerant state referred to as preconditioning (<xref ref-type="bibr" rid="ref90">Stetler et al., 2014</xref>). HPC entails the application of mild and transient hypoxia, triggering cellular protection and enhancing the cells&#x2019; capacity to endure fluctuating O<sub>2</sub> levels (<xref ref-type="bibr" rid="ref50">Li et al., 2017</xref>). Several studies demonstrated the beneficial outcomes of HPC on various neurodegenerative diseases including seizures and epilepsy (<xref ref-type="bibr" rid="ref32">Gao et al., 2014</xref>; <xref ref-type="bibr" rid="ref102">Yang et al., 2013</xref>; <xref ref-type="bibr" rid="ref68">Pohle and Rauca, 1994</xref>). Despite the potential of hypoxic preconditioning as a future treatment approach for neurodegenerative diseases, the field still remains understudied. Consequently, a deeper understanding of the mechanisms triggered by mild hypoxia treatment, as these mechanisms could be involved in the neuroprotective benefits, is essential to pave the way for the development of future treatment possibilities. This study aimed to further explore the biochemical changes triggered by mild hypoxia, with a particular emphasis on mitochondria, the central hub of O<sub>2</sub> consumption.</p>
<sec id="sec25">
<label>4.1</label>
<title>Seizure threshold</title>
<p>To investigate the neuroprotective potential of the used HPC protocol, we assessed its impact on the seizure threshold using the acute PTZ seizure mouse model. Our results demonstrated a positive influence on the seizure threshold after HPC. This observation is consistent with the beneficial outcomes of HPC on seizures and epilepsy documented in various studies (<xref ref-type="bibr" rid="ref32">Gao et al., 2014</xref>, <xref ref-type="bibr" rid="ref102">Yang et al., 2013</xref>, <xref ref-type="bibr" rid="ref68">Pohle and Rauca, 1994</xref>).</p>
</sec>
<sec id="sec26">
<label>4.2</label>
<title>Mitochondrial respiration</title>
<p>To explore the effects of varying O<sub>2</sub> levels on mitochondrial respiration, high-resolution respirometry experiments were performed under both air-saturated O<sub>2</sub> conditions and O<sub>2</sub> levels more aligned with physiological conditions for brain tissue cells (<xref ref-type="bibr" rid="ref39">Hadanny and Efrati, 2020</xref>). Interestingly, our investigation of mitochondrial respiration under different O<sub>2</sub> levels revealed diverse results. When measurements were conducted near air-saturated O<sub>2</sub> levels, we observed a decrease in N-linked LEAK respiration and S-linked ET capacity following HPC treatment compared to the Ctrl group (mass-specific O<sub>2</sub> flux, CS-specific O<sub>2</sub> flux). Moreover, the CS-specific O<sub>2</sub> flux for N- and NS-linked OXPHOS, along with NS-linked ET capacity, also exhibited significant reductions after hypoxia treatment in comparison to the Ctrl group. Taken together, these results indicate that evaluating mitochondrial respiration following HPC near air-saturated O<sub>2</sub> conditions leads to a reduction in O<sub>2</sub> consumption compared to Ctrl conditions, with notable effects observed particularly on N-linked LEAK and S-linked ET capacity.</p>
<p>However, when measurements were conducted at O<sub>2</sub> levels closer to intracellular tissue normoxia, both mass-specific and CS-specific O<sub>2</sub> flux across all tested states exhibited a significant increase following HPC treatment in comparison to the Ctrl group. Additionally, the <italic>FCR</italic> of N-linked LEAK respiration displayed a significant increase in comparison to the Ctrl group. The observed elevation in mass-specific O<sub>2</sub> flux post-HPC, along with unchanged <italic>FCR</italic> values during OXPHOS and ET capacity but an augmentation in O<sub>2</sub> flux and <italic>FCR</italic> during LEAK respiration, implies HPC treatment triggers mt-quality changes which may be attributed to a rise in LEAK respiration. This interpretation gains further support from the observed decreased <italic>P</italic>-<italic>L</italic> control efficiency post-hypoxia, indicative of a less tightly coupled system (<xref ref-type="bibr" rid="ref36">Gnaiger et al., 2020</xref>; <xref ref-type="bibr" rid="ref35">Gnaiger, 2020</xref>).</p>
<p>These results collectively indicate that Ctrl and HPC-treated mitochondria exhibit distinct responses to experimental O<sub>2</sub> conditions. The main observation is a direct dependence of respiration on oxygen concentrations in controls. By contrast, HPC treated mice do not display markedly reduced respiration at tissue normoxic conditions as compared to air saturated conditions.</p>
</sec>
<sec id="sec27">
<label>4.3</label>
<title>Mitochondrial ROS production</title>
<p>Our findings demonstrated an elevated CS-specific H<sub>2</sub>O<sub>2</sub> flux during the N-linked LEAK state following HPC. Additionally, H<sub>2</sub>O<sub>2</sub> production significantly increased, particularly during N-linked OXPHOS (mass-specific and CS-specific H<sub>2</sub>O<sub>2</sub> flux as well as <italic>J</italic><sub>H2O2</sub>/<italic>J</italic><sub>O2</sub>). Moreover, mass-specific H<sub>2</sub>O<sub>2</sub> flux and the <italic>J</italic><sub>H2O2</sub>/<italic>J</italic><sub>O2</sub> ratio, both assessed after adding Ama to determine the maximal contribution of CIII to ROS production, exhibited a significant decrease following hypoxia treatment. These observations suggest increased ROS production primarily originating from CI, while the contribution of CIII to ROS generation appears to be diminished. Furthermore, the observed rise in O<sub>2</sub> consumption after HPC under intracellular tissue normoxia may be partly attributed to the increased generation of ROS compared to the control.</p>
<p>Mitochondrial ROS production under hypoxic conditions has a dual impact. On one hand, it can lead to cellular damage, while on the other hand, it can activate signaling pathways (<xref ref-type="bibr" rid="ref4">Azzi, 2022</xref>). After a hypoxic phase when the ETS is highly reduced and O<sub>2</sub> levels rise again, ROS production can be stimulated, causing oxidative tissue damage (<xref ref-type="bibr" rid="ref71">Qin et al., 2009</xref>). Current evidence points to CI as the source of increased ROS production contributing to tissue injuries (<xref ref-type="bibr" rid="ref12">Brand et al., 2016</xref>; <xref ref-type="bibr" rid="ref37">Gorenkova et al., 2013</xref>). However, in our experiments, it would be intriguing to pinpoint the specific ROS production site within CI. CI has two known ROS production sites: I<sub>Q</sub>, believed to be active during RET at the ubiquinone binding site, and I<sub>F</sub>, located at the flavin site of CI and suggested to be active during forward electron transfer (<xref ref-type="bibr" rid="ref33">Gibbs et al., 2023</xref>; <xref ref-type="bibr" rid="ref12">Brand et al., 2016</xref>). The I<sub>Q</sub> site has been associated with ischemia&#x2013;reperfusion damage, and experiments blocking ROS production specifically from this site, without inhibiting respiration or OXPHOS, have shown protective effects against ischemia&#x2013;reperfusion injuries when RET was responsible for ROS generation (<xref ref-type="bibr" rid="ref12">Brand et al., 2016</xref>; <xref ref-type="bibr" rid="ref105">Yin et al., 2021</xref>).</p>
<p>However, we noticed that the observed rise in ROS production corresponds to less than 2% (<italic>J</italic><sub>H2O2</sub>/<italic>J</italic><sub>O2</sub>&#x002A;100) of the consumed O<sub>2</sub>. This falls within the range of ROS production observed under physiological conditions, where it is estimated to be as high as 2% of the consumed O<sub>2</sub> (<xref ref-type="bibr" rid="ref110">Zorov et al., 2014</xref>). As concluded from our mitochondrial morphology and dynamics study, the measured ROS production seems to remain below the threshold that causes damage, indicating that the slight increase in ROS levels might function as a mechanism for cell signaling and protection. Furthermore, this concept closely resembles the principle of preconditioning, where cells and tissues are exposed to a non-lethal stressor, whether of the same or different origin, leading to cellular and tissue protection (<xref ref-type="bibr" rid="ref50">Li et al., 2017</xref>; <xref ref-type="bibr" rid="ref90">Stetler et al., 2014</xref>).</p>
<p>Interestingly, our study suggests that HPC triggers controlled ROS production via CI, maintaining ROS levels below the toxic threshold. This controlled ROS generation could potentially activate various pathways, such as the HIF1 and ERK pro-survival pathways, contributing to the preconditioning effects (<xref ref-type="bibr" rid="ref52">Liu et al., 2005</xref>; <xref ref-type="bibr" rid="ref30">Fryer et al., 2001</xref>).</p>
<p>The finding that CI is the primary source of increased ROS production, with a reduced role for CIII, contradicts findings from other studies that suggested CIII as the main ROS source for cell signaling (<xref ref-type="bibr" rid="ref6">Bell et al., 2007</xref>). For instance, it is argued that ROS originating from CIII theoretically has a more direct path to the cytosol, where they engage in cell signaling (<xref ref-type="bibr" rid="ref24">Diebold and Chandel, 2016</xref>). Moreover, there is a proposition that actually the O<sub>2</sub><sup>&#x2022;-</sup> derived from CIII possesses the cellular signaling and cytoprotective effects, providing additional support for the significance of CIII in this context (<xref ref-type="bibr" rid="ref55">Malinska et al., 2010</xref>).</p>
<p>In an intriguing study conducted by <xref ref-type="bibr" rid="ref38">Guzy et al. (2005)</xref>, these authors observed the crucial role of ROS in activating the HIF1 pathway. However, they propose that HIF1&#x03B1; stabilization is predominantly attributed to H<sub>2</sub>O<sub>2</sub> originating from CIII, a notion supported by the fact that blocking CIII abolishes this stabilizing effect. Nevertheless, it is important to highlight that their discussion recognizes the possibility that interfering with CIII may also perturb the electron flow in CI and CII, casting uncertainty on the involvement of these complexes. Furthermore, the same study emphasized that O<sub>2</sub><sup>&#x2022;-</sup> is not directly necessary for HIF1&#x03B1; stabilization, highlighting the importance of H<sub>2</sub>O<sub>2</sub> instead (<xref ref-type="bibr" rid="ref38">Guzy et al., 2005</xref>).</p>
<p>In line with the study of <xref ref-type="bibr" rid="ref38">Guzy et al. (2005)</xref>, the prevailing consensus continues to recognize H<sub>2</sub>O<sub>2</sub> as the primary ROS involved in cell signaling (<xref ref-type="bibr" rid="ref24">Diebold and Chandel, 2016</xref>). For instance, elevated H<sub>2</sub>O<sub>2</sub> levels can induce HIF1&#x03B1; accumulation, even under air-saturated O<sub>2</sub> conditions (<xref ref-type="bibr" rid="ref76">Richard et al., 2000</xref>; <xref ref-type="bibr" rid="ref18">Chandel et al., 2000</xref>), and that the administration of a moderate dose of H<sub>2</sub>O<sub>2</sub> to cells before subjecting them to ischemic conditions can lead to preconditioning (<xref ref-type="bibr" rid="ref48">Lebuffe et al., 2003</xref>). Furthermore, CI inhibition and the reduction of mitochondrial ROS levels in the cell culture can effectively prevent HIF1&#x03B1; accumulation, even under conditions with 1.5% O<sub>2</sub> (<xref ref-type="bibr" rid="ref18">Chandel et al., 2000</xref>; <xref ref-type="bibr" rid="ref1">Agani et al., 2000</xref>).</p>
<p>Taken together, these studies support the assumption that H<sub>2</sub>O<sub>2</sub> originating from CI might be released from the mitochondrial matrix and might play a role in the activation of various cell signaling processes, including the HIF pathway.</p>
<p>The significant disparities observed across various studies regarding the role of ROS in cell signaling, such as the activation of the HIF1 pathway, may be attributed to differences in experimental conditions. These discrepancies encompass the utilization of distinct cell types or tissues, including cancer cell lines, which may respond differently from physiologically relevant cells. Additionally, <italic>in vitro</italic> experiments might create a more artificial environment. The techniques employed for measuring ROS production may also introduce variations in outcomes. Our objective was to tackle these issues by subjecting mice to treatments, enabling us to investigate the impact of HPC on the organism instead of focusing solely on individual cells. Furthermore, we focused on precisely measuring mitochondrial respiration and ROS production while assessing the involvement of various respiratory complexes at a high resolution.</p>
<p>Importantly, our measurements were conducted 17&#x202F;h post-hypoxia rather than during or immediately after the hypoxic phase. This time point variation may contribute to the discrepancies in results compared to findings in other publications. However, the regulation of mitochondrial ROS generation <italic>in vivo</italic> is still a relatively underexplored area, given that a substantial portion of our current insights has been gleaned from investigations conducted on isolated mitochondria or cells <italic>in vitro</italic>. Numerous factors, including O<sub>2</sub> levels, electron availability for the ETS, the quantity of electron carriers, the redox state of these carriers, and the mitochondrial membrane potential, can all exert an influence on the generation of mitochondrial ROS (<xref ref-type="bibr" rid="ref24">Diebold and Chandel, 2016</xref>).</p>
<p>To the best of our knowledge, this study represents the first attempt, to employ high-resolution respirometry for evaluating mitochondrial respiration and ROS production in brain tissue homogenates following <italic>in vivo</italic> exposure to hypoxia.</p>
</sec>
<sec id="sec28">
<label>4.4</label>
<title>Mitochondrial dynamics</title>
<p>The evaluation of mitochondrial dynamics following HPC treatment demonstrated an elevation in the mRNA expression levels of fusion factors <italic>Mfn1</italic>, <italic>Mfn2</italic>, and <italic>Opa1</italic> within the rapid HPC group. This observation is in line with reported augmentation in mitochondrial fusion immediately after hypoxia (<xref ref-type="bibr" rid="ref54">Macdonald et al., 2016</xref>; <xref ref-type="bibr" rid="ref2">Akepati et al., 2008</xref>). This notion is supported by microscopy images depicting heightened mitochondrial fusion immediately after hypoxia. Additionally, the analysis of mitochondrial morphology demonstrated an elevated average mitochondrial size coupled with a reduction in mitochondrial number per cell area, further bolstering the inference of increased mitochondrial fusion immediately post-hypoxia.</p>
<p>Increased levels of both MFN1 and MFN2 have also been linked to the perinuclear aggregation of mitochondria, a phenomenon associated with the localized release of second messengers, including ROS, towards the nucleus. For instance, these effects have been demonstrated to play a crucial role in the complete activation of HIF1 target genes (<xref ref-type="bibr" rid="ref3">Al-Mehdi et al., 2012</xref>). The rise in <italic>Mfn1</italic> and <italic>Mfn2</italic> mRNA levels post-hypoxia could potentially lead to augmented perinuclear mitochondrial accumulation, influencing processes such as the activation of HIF1 target genes.</p>
<p>OPA1 not only participates in the fusion of the mitochondrial inner membrane but also plays essential roles in functions like <italic>cristae</italic> morphology and the maintenance of mitochondrial DNA. Moreover, it contributes to reinforcing connections within the <italic>cristae</italic>, which in turn aids in sequestering cytochrome <italic>c</italic> and influencing apoptosis (<xref ref-type="bibr" rid="ref23">Del Dotto et al., 2017</xref>; <xref ref-type="bibr" rid="ref60">Olichon et al., 2003</xref>; <xref ref-type="bibr" rid="ref29">Frezza et al., 2006</xref>). Therefore, the upregulation of <italic>Opa1</italic> expression following hypoxia treatment has the potential to enhance cell survival.</p>
<p>Seventeen hours after hypoxia, mRNA levels of <italic>Mfn1</italic> and <italic>Mfn2</italic> did not exhibit significant changes, while the expression of the fusion factor <italic>Opa1</italic> showed a statistically significant increase compared to Ctrl samples. Notably, microscopy images of stained mitochondria at the same time point revealed mixed results&#x2014;some cells exhibited heightened mitochondrial fusion, while the majority displayed a mitochondrial fusion level similar to the Ctrl. Additionally, analyses of mitochondrial morphology showed no alterations in the mean mitochondrial size and mitochondrial number per cell area when compared to the Ctrl group. The observed increase in <italic>Opa1</italic> expression 17&#x202F;h after hypoxia might trigger survival signaling. However, it could also contribute to mitochondrial fusion, potentially explaining the presence of fused mitochondria in some cells.</p>
<p>Additionally, we did not detect any changes in the mitochondrial area relative to the cell area both immediately after hypoxia and 17&#x202F;h later. This suggests that, under the conditions employed, there was no biogenesis of new mitochondria.</p>
<p>In summary, the findings suggest an immediate increase in mitochondrial fusion following hypoxia, potentially being part of an adaptive process often associated with cell survival (<xref ref-type="bibr" rid="ref64">Park et al., 2014</xref>). However, 17&#x202F;h after hypoxia, the majority of cells contained mitochondria with morphology similar to those under control conditions, although some cells displayed heightened mitochondrial fusion. Interestingly, there were no indications of increased mitochondrial fission, typically linked to elevated stress levels, mitochondrial dysfunction, and cell death (<xref ref-type="bibr" rid="ref95">Tilokani et al., 2018</xref>). This suggests that our treatment did not evoke severe cellular stress resulting in tissue damage or cell death; instead, it remained below the threshold of harmful hypoxia. Enhanced mitochondrial fusion is frequently linked to mild stress responses and associated with mechanisms that promote cell survival, protecting against mitochondrial degradation (<xref ref-type="bibr" rid="ref72">Rambold et al., 2011</xref>). This kind of mild stress-triggered hyperfusion of mitochondria is believed to be regulated, among other factors, by OPA1 and MFN1 (<xref ref-type="bibr" rid="ref97">Tondera et al., 2009</xref>). Nonetheless, it is important to acknowledge that although we did observe heightened mitochondrial fusion following hypoxia, only a subset of cells displayed an elevated mitochondrial fusion phenotype 17&#x202F;h later. This implies that in our experimental configuration, mitochondrial fusion might have a limited role in the neuroprotective effects observed hours after HPC treatment.</p>
</sec>
</sec>
<sec sec-type="conclusions" id="sec29">
<label>5</label>
<title>Conclusion</title>
<p>In this study, we were able to show the critical role of O<sub>2</sub> levels during mitochondrial respiration measurements, as changes in O<sub>2</sub> levels can significantly influence the results and potentially lead to misleading conclusions. In our particular context, it is crucial to perform respiration measurements under O<sub>2</sub> levels that closely resemble physiological conditions since our primary objective is to gain insights into how cells and mitochondria adapt to varying O<sub>2</sub> levels. Remarkably, when hypoxia-exposed mitochondria were subjected to air-saturated, effectively hyperoxic conditions, they tended to exhibit reduced O<sub>2</sub> consumption compared to control samples. Conversely, under O<sub>2</sub> levels closer to intracellular tissue normoxia, their O<sub>2</sub> consumption rate increased when compared to the control. This elevated O<sub>2</sub> consumption appeared to be associated with an increase in the production of ROS, which remained within the physiological range and primarily emanated from CI, while the contribution of CIII appeared to be diminished in this context. We speculate that this heightened ROS production might play a role in initiating cell signaling, such as the activation of the HIF1 pathway, even in the presence of physiological O<sub>2</sub> concentrations.</p>
<p>Although we did observe an increase in mitochondrial fusion after hypoxia, this effect was only noticeable in a subset of cells 17&#x202F;h later. This suggests that, within the context of our experimental setup, mitochondrial fusion may play a minor role in the neuroprotective effects observed hours after HPC treatment. The observed increase in <italic>Mfn1</italic> and <italic>Mfn2</italic> levels might have resulted in a greater aggregation of mitochondria around the nucleus, and when combined with a controlled release of ROS towards the nucleus, it would have the potential to amplify the activation of HIF1 target genes. This collaborative effect could promote pro-survival and neuroprotective signaling, possibly also supported by <italic>Opa1</italic>.</p>
<p>While we did observe an increased seizure threshold, indicating enhanced resistance to epileptic seizures and highlighting the neuroprotective effects of applied HPC protocol, our present results do not allow us to definitively establish a direct connection between the observed post-HPC changes and the protective effects noted.</p>
<p>The results of this study offer insights into the mechanisms that underlie hypoxic preconditioning. These insights have the potential to improve our comprehension of events following mild hypoxia exposure, which could play a role in the neuroprotective and pro-survival effects associated with HPC.</p>
</sec>
<sec id="sec30">
<label>6</label>
<title>Outlook and limitations</title>
<p>In future experiments, it will be vital to explore whether the observed rise in ROS production originating from CI can indeed initiate cellular signaling, such as activating the HIF1 pathway, in response to hypoxia exposure. Additionally, it would be important to pinpoint the exact site within CI responsible for ROS generation and its role in protective effects by employing specific CI inhibitors.</p>
<p>Furthermore, we assessed mitochondrial respiration in tissue samples from the hippocampus, motor cortex, and striatum near air-saturated O<sub>2</sub> conditions. However, in measurements under conditions of intracellular tissue normoxia, we were only able to conduct experiments using samples from the hippocampus and striatum. This limitation arose because we utilized the same samples to measure ROS production, and our capacity to perform measurements on all three tissue samples simultaneously was constrained due to a limited number of Oroboros devices.</p>
<p>Moreover, although the Macro tool we created simplifies the analysis of mitochondrial morphology, it still requires manual adjustments to correct false positives.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="sec31">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="sec" rid="sec38">Supplementary material</xref>, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec sec-type="ethics-statement" id="sec32">
<title>Ethics statement</title>
<p>The animal study was approved by Animal Ethics Committee of the Medical University Innsbruck and the Austrian Animal Experimentation Ethics Board. The study was conducted in accordance with the local legislation and institutional requirements.</p>
</sec>
<sec sec-type="author-contributions" id="sec33">
<title>Author contributions</title>
<p>LB: Investigation, Writing &#x2013; review &#x0026; editing, Validation, Writing &#x2013; original draft, Data curation, Visualization, Formal analysis. CD: Supervision, Methodology, Investigation, Writing &#x2013; review &#x0026; editing. BF: Data curation, Investigation, Writing &#x2013; review &#x0026; editing, Formal analysis. TK: Methodology, Writing &#x2013; review &#x0026; editing, Supervision, Investigation. AF: Investigation, Writing &#x2013; review &#x0026; editing, Formal analysis. KS: Writing &#x2013; review &#x0026; editing, Investigation, Formal analysis. CS: Project administration, Supervision, Conceptualization, Funding acquisition, Writing &#x2013; original draft. EG: Methodology, Writing &#x2013; original draft, Software, Supervision, Resources, Validation, Conceptualization, Project administration.</p>
</sec>

<ack><title>Acknowledgments</title>
<p>We express our gratitude to Angela Steck, Ingeborg Kapeller, Luca Zangrandi, Marco Di Marcello, Manuela Passrugger, Marta Suarez Cubero, Lucie Simonin, Leila Nerdeux and Marcel Tisch for their valuable technical support and for sharing their laboratory expertise. Additionally, we extend our thanks to Frank Edenhofer for granting permission to conduct experiments in his lab. Furthermore, we would like to recognize the vital contribution of the mice involved in the experiments, whose lives were taken in the pursuit of scientific understanding. Their sacrifice has been crucial for the progress of this research. Findings from this study have been previously published online within LB&#x2019;s Ph.D. thesis.</p>
</ack>
<sec sec-type="COI-statement" id="sec35">
<title>Conflict of interest</title>
<p>EG is the CEO of Oroboros Instruments.</p>
<p>The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="ai-statement" id="sec36">
<title>Generative AI statement</title>
<p>The authors declare that Gen AI was used in the creation of this manuscript. Grammarly and ChatGPT (August 3 Version) were utilized to enhance the writing quality and ensure grammatical correctness.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p>
</sec>
<sec sec-type="disclaimer" id="sec37">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec sec-type="supplementary-material" id="sec38">
<title>Supplementary material</title>
<p>The Supplementary material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fnmol.2025.1628567/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fnmol.2025.1628567/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Data_Sheet_1.pdf" mimetype="application/pdf" xmlns:xlink="http://www.w3.org/1999/xlink" id="SM1"><label>SUPPLEMENTARY FIGURE S1</label><caption><p>Mitochondrial respiration and H<sub>2</sub>O<sub>2</sub> production assessed under tissue normoxia (O<sub>2</sub> concentration 30 to 40 &#x03BC;M). Representative traces of mitochondrial respiration <bold>(A)</bold> and H<sub>2</sub>O<sub>2</sub> production <bold>(B)</bold> simultaneously measured by high-resolution respirometry (Oroboros FluoRespirometer). The experimental protocol closely matched the SUIT protocol in <xref ref-type="fig" rid="fig3">Figure 2</xref> (main text). 1PMG: Sequential injections of pyruvate (P; 5&#x202F;mM), malate (M; 2&#x202F;mM), and glutamate (G; 10&#x202F;mM) to initiate N-linked LEAK respiration N<italic><sub>L</sub></italic>. 2D: A kinetically saturating ADP concentration (D; 2.5&#x202F;mM) induced N-linked OXPHOS N<italic><sub>P</sub></italic>. 3S: CII-substrate succinate (S; 50&#x202F;mM) added to evaluate NS-pathway OXPHOS capacity NS<italic><sub>P</sub></italic> (CI- and CII-linked). 4U: Stepwise titrations of the uncoupler carbonyl cyanide chlorophenylhydrazone CCCP (U; 1.5&#x2013;2.5&#x202F;&#x03BC;M) to reach maximum respiration as an estimate of NS-pathway ET capacity NS<italic><sub>E</sub></italic>. 5Rot: Inhibition of CI by rotenone (Rot; 0.5&#x202F;&#x03BC;M) to measure S-linked ET capacity S<italic><sub>E</sub></italic>. 6Ama: Inhibition of CIII by antimycin A (Ama; 2.5&#x202F;&#x03BC;M) to assess residual oxygen consumption <italic>Rox</italic> for baseline correction of O<sub>2</sub> flux in all mitochondrial respiratory states. During sections of reoxygenations, marked by shaded bars, fluxes cannot be measured. <bold>(A)</bold> The blue line shows O<sub>2</sub> concentration [&#x03BC;M] with a zoom into the 50 &#x03BC;M range (compare <xref ref-type="fig" rid="fig3">Figure 2</xref>), the red line shows O<sub>2</sub> flux per tissue wet mass [pmol<sub>&#x00B7;</sub>s<sup>&#x2212;1</sup><sub>&#x00B7;</sub>mg<sup>&#x2212;1</sup>]. Marks (vertical bars) for evaluation of rates were set at O<sub>2</sub> concentrations of 30 to 40&#x202F;&#x03BC;M. O<sub>2</sub> levels were adjusted by introducing N<sub>2</sub> or H<sub>2</sub> or opening the chambers. <bold>(B)</bold> Fluorometric signal (black line), calculated as equivalent H<sub>2</sub>O<sub>2</sub> concentration [&#x03BC;M] (note that the actual H<sub>2</sub>O<sub>2</sub> concentration is maintained at zero in the AmR assay). The green line denotes H<sub>2</sub>O<sub>2</sub> flux per tissue mass [pmol<sub>&#x00B7;</sub>s<sup>&#x2212;1</sup><sub>&#x00B7;</sub>mg<sup>&#x2212;1</sup>]. Changes of fluorescence sensitivity over time were assessed by sequentially titrating H<sub>2</sub>O<sub>2</sub> (0.1&#x202F;&#x03BC;M) in the course of the experiment. The black bar indicates the maximal contribution of CIII to ROS production. Titration spikes are disturbances of the traces of O<sub>2</sub> flux apparent as downwards spikes and of H<sub>2</sub>O<sub>2</sub> flux apparent as upwards spikes.</p></caption></supplementary-material>
<supplementary-material xlink:href="Data_Sheet_1.pdf" mimetype="application/pdf" xmlns:xlink="http://www.w3.org/1999/xlink" id="SM2"><label>SUPPLEMENTARY FIGURE S2</label><caption><p>Effect of AmR on mitochondrial respiration in brain tissue of untreated mice assessed under tissue normoxia. Mitochondrial respiration measured at O<sub>2</sub> concentrations ranging from 30-40&#x202F;&#x03BC;M, either in the absence of the H<sub>2</sub>O<sub>2</sub> fluorescence probe (w/o AmR) or its presence (AmR+fluorescence light). See legend of <xref ref-type="supplementary-material" rid="SM1">Supplementary Figure S1</xref> for respiratory states and rates. Mass-specific O<sub>2</sub> flux [pmol<sub>&#x00B7;</sub>s<sup>&#x2212;1</sup><sub>&#x00B7;</sub>mg<sup>&#x2212;1</sup>] was normalized for wet tissue mass. Citrates synthase activity (CS [IU]) was used as a mitochondrial marker for expression of mt-specific O<sub>2</sub> flux [pmol<sub>&#x00B7;</sub>s<sup>&#x2212;1</sup><sub>&#x00B7;</sub>IU<sup>&#x2212;1</sup>]. Flux control ratios <italic>FCR</italic> were normalized for maximal O<sub>2</sub> flux NS<italic><sub>E</sub></italic>. Samples were harvested from the hippocampus and striatum of untreated C57BL6/J mice. Data represent medians &#x00B1; IQR and statistical significance was determined using the Mann-Whitney U test, with a significance level set at &#x2264; 0.05.</p></caption></supplementary-material>
<supplementary-material xlink:href="Data_Sheet_1.pdf" mimetype="application/pdf" xmlns:xlink="http://www.w3.org/1999/xlink" id="SM3"><label>SUPPLEMENTARY FIGURE S3</label><caption><p>Effect of AmR on mitochondrial respiration of hippocampus and striatum from HPC treated mice assessed under tissue normoxia. Mitochondrial respiration measured at O<sub>2</sub> concentrations of 30-40&#x202F;&#x03BC;M, either in the absence of the H<sub>2</sub>O<sub>2</sub> fluorescence probe (w/o AmR) or its presence (AmR+fluorescence light). See legend of <xref ref-type="supplementary-material" rid="SM1">Supplementary Figure S1</xref> for respiratory states and rates, and legend of <xref ref-type="supplementary-material" rid="SM2">Supplementary Figure S2</xref> for normalization of O<sub>2</sub> flux. Data represent medians &#x00B1; IQR and statistical significance was determined using the Mann-Whitney U test, with a significance level set at &#x2264; 0.05.</p></caption></supplementary-material>
<supplementary-material xlink:href="Data_Sheet_1.pdf" mimetype="application/pdf" xmlns:xlink="http://www.w3.org/1999/xlink" id="SM4"><label>SUPPLEMENTARY FIGURE S4</label><caption><p>Effect of AmR on respiratory control efficiencies in controls and HPC-treated mice in hippocampus and striatum assessed under tissue normoxia. Control ratios in the presence or absence of H<sub>2</sub>O<sub>2</sub> fluorescence probe, AmR. <italic>P</italic>-<italic>L</italic> control efficiency = (N<italic><sub>P</sub></italic>&#x2212;N<italic><sub>L</sub></italic>)/N<italic><sub>P</sub></italic> = 1&#x2212;N<italic><sub>L</sub></italic>/N<italic><sub>P</sub></italic>; <italic>E</italic>-<italic>P</italic> control efficiency = (NS<italic><sub>E</sub></italic>&#x2212;NS<italic><sub>P</sub></italic>)/NS<italic><sub>E</sub></italic> = 1&#x2212;NS<italic><sub>P</sub></italic>/NS<italic><sub>E</sub></italic>. See legend of <xref ref-type="supplementary-material" rid="SM1">Supplementary Figure S1</xref> for respiratory states and rates. Data represent medians &#x00B1; IQR. Statistical test: Mann-Whitney U test, &#x2264;&#x202F;0.05, was defined as statistically significant.</p></caption></supplementary-material>
<supplementary-material xlink:href="Data_Sheet_1.pdf" mimetype="application/pdf" xmlns:xlink="http://www.w3.org/1999/xlink" id="SM5"><label>SUPPLEMENTARY FIGURE S5</label><caption><p>Effect of HPC-treatment on mitochondrial respiration of different brain areas assessed under effectively hyperoxic conditions near air-saturation. Homogenates were prepared from hippocampus, motor cortex, and striatum of Ctrl and HPC-treated C57BL6/J mice. See legend of <xref ref-type="supplementary-material" rid="SM1">Supplementary Figure S1</xref> for respiratory states and rates, and legend of <xref ref-type="supplementary-material" rid="SM2">Supplementary Figure S2</xref> for normalization of O<sub>2</sub> flux. Data represent medians &#x00B1; IQR. Statistical test: Mann-Whitney U test, &#x2264; 0.05, was defined as statistically significant.</p></caption></supplementary-material>
<supplementary-material xlink:href="Data_Sheet_1.pdf" mimetype="application/pdf" xmlns:xlink="http://www.w3.org/1999/xlink" id="SM6"><label>SUPPLEMENTARY FIGURE S6</label><caption><p>Effect of HPC-treatment on respiratory control efficiencies in different brain areas assessed under effectively hyperoxic conditions near air-saturation. See legend of <xref ref-type="supplementary-material" rid="SM1">Supplementary Figure S1</xref> for respiratory states and rates, and legend of <xref ref-type="supplementary-material" rid="SM4">Supplementary Figure S4</xref> for respiratory control efficiencies. Data represent medians &#x00B1; IQR. Statistical test: Mann-Whitney U test, &#x2264; 0.05, was defined as statistically significant.</p></caption></supplementary-material>
<supplementary-material xlink:href="Data_Sheet_1.pdf" mimetype="application/pdf" xmlns:xlink="http://www.w3.org/1999/xlink" id="SM7"><label>SUPPLEMENTARY FIGURE S7</label><caption><p>Effect of HPC-treatment on mitochondrial respiration of hippocampus and striatum assessed under intracellular tissue normoxia. Tissue homogenates of Ctrl and HPC-treated C57BL6/J mice were examined under O<sub>2</sub> concentrations of 30&#x2013;40&#x202F;&#x03BC;M. See legend of <xref ref-type="supplementary-material" rid="SM1">Supplementary Figure S1</xref> for respiratory states and rates, and legend of <xref ref-type="supplementary-material" rid="SM2">Supplementary Figure S2</xref> for normalization of O<sub>2</sub> flux. Data represent medians &#x00B1; IQR. Statistical test: Mann-Whitney U test, &#x2264;&#x202F;0.05, was defined as statistically significant.</p></caption></supplementary-material>
<supplementary-material xlink:href="Data_Sheet_1.pdf" mimetype="application/pdf" xmlns:xlink="http://www.w3.org/1999/xlink" id="SM8"><label>SUPPLEMENTARY FIGURE S8</label><caption><p>Effect of HPC-treatment on respiratory control efficiencies of hippocampus and striatum assessed under intracellular tissue normoxia. Measurements on brain homogenates of Ctrl and HPC-treated C57BL6/J mice performed under O<sub>2</sub> concentrations of 30&#x2013;40&#x202F;&#x03BC;M. See legend of <xref ref-type="supplementary-material" rid="SM1">Supplementary Figure S1</xref> for respiratory states and rates, and legend of <xref ref-type="supplementary-material" rid="SM4">Supplementary Figure S4</xref> for respiratory control efficiencies. Data represent medians &#x00B1; IQR. Statistical test: Mann-Whitney U test, &#x2264; 0.05, was defined as statistically significant.</p></caption></supplementary-material>
<supplementary-material xlink:href="Data_Sheet_1.pdf" mimetype="application/pdf" xmlns:xlink="http://www.w3.org/1999/xlink" id="SM9"><label>SUPPLEMENTARY FIGURE S9</label><caption><p>Effect of HPC-treatment on net mitochondrial H<sub>2</sub>O<sub>2</sub> production of hippocampus and striatum assessed under tissue normoxia. Measurements on tissue homogenates from Ctrl and HPC-treated C57BL6/J mice were conducted while maintaining O<sub>2</sub> concentration within the range of 30&#x2013;40&#x202F;&#x03BC;M. The <italic>J</italic><sub>H2O2</sub>/<italic>J</italic><sub>O2</sub> ratio is the proportion of H<sub>2</sub>O<sub>2</sub> produced to O<sub>2</sub> consumed. H<sub>2</sub>O<sub>2</sub> flux was normalized to O<sub>2</sub> flux in the absence of AmR. See legend of <xref ref-type="supplementary-material" rid="SM1">Supplementary Figure S1</xref> for respiratory states and rates, and legend of <xref ref-type="supplementary-material" rid="SM2">Supplementary Figure S2</xref> for normalization of H<sub>2</sub>O<sub>2</sub> flux. Data represent medians &#x00B1; IQR. Statistical test: Mann-Whitney U test, &#x2264; 0.05, was defined as statistically significant.</p></caption></supplementary-material>
<supplementary-material xlink:href="Data_Sheet_1.pdf" mimetype="application/pdf" xmlns:xlink="http://www.w3.org/1999/xlink" id="SM10"><label>SUPPLEMENTARY FIGURE S10</label><caption><p>Effect of HPC-treatment on maximal contribution of CIII to mitochondrial H<sub>2</sub>O<sub>2</sub> production in hippocampus and striatum under tissue normoxia. The fluorescence assay AmR was employed to determine H<sub>2</sub>O<sub>2</sub> flux. The maximal contribution of CIII to the net production of H<sub>2</sub>O<sub>2</sub> was measured in tissue homogenates from control and HPC-treated C57BL6/J mice, using the CIII inhibitor antimycin A at O<sub>2</sub> concentrations of 30&#x2013;40&#x202F;&#x03BC;M. See legend of <xref ref-type="supplementary-material" rid="SM1">Supplementary Figure S1</xref> for respiratory states and rates, and legend of <xref ref-type="supplementary-material" rid="SM2">Supplementary Figures S2</xref>, <xref ref-type="supplementary-material" rid="SM9">S9</xref> for normalization of H<sub>2</sub>O<sub>2</sub> flux. Data represent medians &#x00B1; IQR. Statistical test: Mann-Whitney U test, &#x2264; 0.05, was defined as statistically significant.</p></caption></supplementary-material>
<supplementary-material xlink:href="Data_Sheet_1.pdf" mimetype="application/pdf" xmlns:xlink="http://www.w3.org/1999/xlink" id="SM11"><label>SUPPLEMENTARY FIGURE S11</label><caption><p>Effect of rapid and delayed HPC-treatment on mRNA expression of critical factors associated with mitochondrial fusion and fission in different brain areas. We conducted real-time qPCR analyses to examine the mRNA expression levels of various target genes in three distinct groups: Control, rapid HPC (samples collected immediately after hypoxia) and delayed HPC (samples obtained 17 hours after hypoxia) in C57BL6/J mice. These assessments were carried out on tissues from the hippocampus, motor cortex, and striatum. The target genes under investigation included fusion factors <italic>Mfn1</italic>, <italic>Mfn2</italic>, and <italic>Opa1</italic>, as well as the fission factor <italic>Drp1</italic>. Expression levels were standardized by comparing them to the expression of a housekeeping gene (<italic>Actb</italic>) and are reported as fold changes in relation to the control. Data represent means &#x00B1; SD and statistical significance was determined using the one-way ANOVA test, with a significance threshold set at &#x2264; 0.05.</p></caption></supplementary-material>
</sec>
<ref-list>
<title>References</title>
<ref id="ref1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agani</surname><given-names>F. H.</given-names></name> <name><surname>Pichiule</surname><given-names>P.</given-names></name> <name><surname>Chavez</surname><given-names>J. C.</given-names></name> <name><surname>Lamanna</surname><given-names>J. C.</given-names></name></person-group> (<year>2000</year>). <article-title>The role of mitochondria in the regulation of hypoxia-inducible factor 1 expression during hypoxia</article-title>. <source>J. Biol. Chem.</source> <volume>275</volume>, <fpage>35863</fpage>&#x2013;<lpage>35867</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M005643200</pub-id>, PMID: <pub-id pub-id-type="pmid">10961998</pub-id></mixed-citation></ref>
<ref id="ref2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akepati</surname><given-names>V. R.</given-names></name> <name><surname>Muller</surname><given-names>E. C.</given-names></name> <name><surname>Otto</surname><given-names>A.</given-names></name> <name><surname>Strauss</surname><given-names>H. M.</given-names></name> <name><surname>Portwich</surname><given-names>M.</given-names></name> <name><surname>Alexander</surname><given-names>C.</given-names></name></person-group> (<year>2008</year>). <article-title>Characterization of OPA1 isoforms isolated from mouse tissues</article-title>. <source>J. Neurochem.</source> <volume>106</volume>, <fpage>372</fpage>&#x2013;<lpage>383</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1471-4159.2008.05401.x</pub-id>, PMID: <pub-id pub-id-type="pmid">18419770</pub-id></mixed-citation></ref>
<ref id="ref3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Mehdi</surname><given-names>A. B.</given-names></name> <name><surname>Pastukh</surname><given-names>V. M.</given-names></name> <name><surname>Swiger</surname><given-names>B. M.</given-names></name> <name><surname>Reed</surname><given-names>D. J.</given-names></name> <name><surname>Patel</surname><given-names>M. R.</given-names></name> <name><surname>Bardwell</surname><given-names>G. C.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Perinuclear mitochondrial clustering creates an oxidant-rich nuclear domain required for hypoxia-induced transcription</article-title>. <source>Sci. Signal.</source> <volume>5</volume>:<fpage>ra47</fpage>. doi: <pub-id pub-id-type="doi">10.1126/scisignal.2002712</pub-id>, PMID: <pub-id pub-id-type="pmid">22763339</pub-id></mixed-citation></ref>
<ref id="ref4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azzi</surname><given-names>A.</given-names></name></person-group> (<year>2022</year>). <article-title>Oxidative stress: what is it?. Can it be measured? Where is it located? Can it be good or bad? Can it be prevented? Can it be cured?</article-title> <source>Antioxidants</source> <volume>11</volume>:<fpage>1431</fpage>. doi: <pub-id pub-id-type="doi">10.3390/antiox11081431</pub-id>, PMID: <pub-id pub-id-type="pmid">35892633</pub-id></mixed-citation></ref>
<ref id="ref5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barone</surname><given-names>F. C.</given-names></name> <name><surname>White</surname><given-names>R. F.</given-names></name> <name><surname>Spera</surname><given-names>P. A.</given-names></name> <name><surname>Ellison</surname><given-names>J.</given-names></name> <name><surname>Currie</surname><given-names>R. W.</given-names></name> <name><surname>Wang</surname><given-names>X.</given-names></name> <etal/></person-group>. (<year>1998</year>). <article-title>Ischemic preconditioning and brain tolerance: temporal histological and functional outcomes, protein synthesis requirement, and interleukin-1 receptor antagonist and early gene expression</article-title>. <source>Stroke</source> <volume>29</volume>, <fpage>1937</fpage>&#x2013;<lpage>1951</lpage>. doi: <pub-id pub-id-type="doi">10.1161/01.STR.29.9.1937</pub-id>, PMID: <pub-id pub-id-type="pmid">9731622</pub-id></mixed-citation></ref>
<ref id="ref6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>E. L.</given-names></name> <name><surname>Klimova</surname><given-names>T. A.</given-names></name> <name><surname>Eisenbart</surname><given-names>J.</given-names></name> <name><surname>Moraes</surname><given-names>C. T.</given-names></name> <name><surname>Murphy</surname><given-names>M. P.</given-names></name> <name><surname>Budinger</surname><given-names>G. R. S.</given-names></name> <etal/></person-group>. (<year>2007</year>). <article-title>The Q(o) site of the mitochondrial complex III is required for the transduction of hypoxic signaling via reactive oxygen species production</article-title>. <source>J. Cell Biol.</source> <volume>177</volume>, <fpage>1029</fpage>&#x2013;<lpage>1036</lpage>. doi: <pub-id pub-id-type="doi">10.1083/jcb.200609074</pub-id>, PMID: <pub-id pub-id-type="pmid">17562787</pub-id></mixed-citation></ref>
<ref id="ref7"><mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Bergmeister</surname><given-names>L.</given-names></name></person-group> (<year>2023</year>) <source>Functional and molecular aspects of hypoxic preconditioning</source>. <publisher-loc>Innsbruck, Austria</publisher-loc>: <publisher-name>Ph.D, Medical University of Innsbruck</publisher-name>.</mixed-citation></ref>
<ref id="ref8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatti</surname><given-names>J.</given-names></name> <name><surname>Nascimento</surname><given-names>B.</given-names></name> <name><surname>Akhtar</surname><given-names>U.</given-names></name> <name><surname>Rhind</surname><given-names>S. G.</given-names></name> <name><surname>Tien</surname><given-names>H.</given-names></name> <name><surname>Nathens</surname><given-names>A.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Systematic review of human and animal studies examining the efficacy and safety of N-acetylcysteine (NAC) and N-acetylcysteine amide (NACA) in traumatic brain injury: impact on neurofunctional outcome and biomarkers of oxidative stress and inflammation</article-title>. <source>Front. Neurol.</source> <volume>8</volume>:<fpage>744</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fneur.2017.00744</pub-id>, PMID: <pub-id pub-id-type="pmid">29387038</pub-id></mixed-citation></ref>
<ref id="ref9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bleier</surname><given-names>L.</given-names></name> <name><surname>Wittig</surname><given-names>I.</given-names></name> <name><surname>Heide</surname><given-names>H.</given-names></name> <name><surname>Steger</surname><given-names>M.</given-names></name> <name><surname>Brandt</surname><given-names>U.</given-names></name> <name><surname>Drose</surname><given-names>S.</given-names></name></person-group> (<year>2015</year>). <article-title>Generator-specific targets of mitochondrial reactive oxygen species</article-title>. <source>Free Radic. Biol. Med.</source> <volume>78</volume>, <fpage>1</fpage>&#x2013;<lpage>10</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2014.10.511</pub-id>, PMID: <pub-id pub-id-type="pmid">25451644</pub-id></mixed-citation></ref>
<ref id="ref10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brand</surname><given-names>M. D.</given-names></name></person-group> (<year>2010</year>). <article-title>The sites and topology of mitochondrial superoxide production</article-title>. <source>Exp. Gerontol.</source> <volume>45</volume>, <fpage>466</fpage>&#x2013;<lpage>472</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.exger.2010.01.003</pub-id>, PMID: <pub-id pub-id-type="pmid">20064600</pub-id></mixed-citation></ref>
<ref id="ref11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brand</surname><given-names>M. D.</given-names></name></person-group> (<year>2016</year>). <article-title>Mitochondrial generation of superoxide and hydrogen peroxide as the source of mitochondrial redox signaling</article-title>. <source>Free Radic. Biol. Med.</source> <volume>100</volume>, <fpage>14</fpage>&#x2013;<lpage>31</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2016.04.001</pub-id>, PMID: <pub-id pub-id-type="pmid">27085844</pub-id></mixed-citation></ref>
<ref id="ref12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brand</surname><given-names>M. D.</given-names></name> <name><surname>Goncalves</surname><given-names>R. L.</given-names></name> <name><surname>Orr</surname><given-names>A. L.</given-names></name> <name><surname>Vargas</surname><given-names>L.</given-names></name> <name><surname>Gerencser</surname><given-names>A. A.</given-names></name> <name><surname>Borch Jensen</surname><given-names>M.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Suppressors of superoxide-H(2)O(2) production at site I(Q) of mitochondrial complex I protect against stem cell hyperplasia and ischemia-reperfusion injury</article-title>. <source>Cell Metab.</source> <volume>24</volume>, <fpage>582</fpage>&#x2013;<lpage>592</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cmet.2016.08.012</pub-id>, PMID: <pub-id pub-id-type="pmid">27667666</pub-id></mixed-citation></ref>
<ref id="ref13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burtscher</surname><given-names>J.</given-names></name> <name><surname>Bean</surname><given-names>C.</given-names></name> <name><surname>Zangrandi</surname><given-names>L.</given-names></name> <name><surname>Kmiec</surname><given-names>I.</given-names></name> <name><surname>Agostinho</surname><given-names>A.</given-names></name> <name><surname>Scorrano</surname><given-names>L.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Proenkephalin derived peptides are involved in the modulation of mitochondrial respiratory control during epileptogenesis</article-title>. <source>Front. Mol. Neurosci.</source> <volume>11</volume>:<fpage>351</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnmol.2018.00351</pub-id>, PMID: <pub-id pub-id-type="pmid">30319356</pub-id></mixed-citation></ref>
<ref id="ref14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burtscher</surname><given-names>J.</given-names></name> <name><surname>Mallet</surname><given-names>R. T.</given-names></name> <name><surname>Burtscher</surname><given-names>M.</given-names></name> <name><surname>Millet</surname><given-names>G. P.</given-names></name></person-group> (<year>2021</year>). <article-title>Hypoxia and brain aging: neurodegeneration or neuroprotection?</article-title> <source>Ageing Res. Rev.</source> <volume>68</volume>:<fpage>101343</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.arr.2021.101343</pub-id>, PMID: <pub-id pub-id-type="pmid">33862277</pub-id></mixed-citation></ref>
<ref id="ref15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burtscher</surname><given-names>J.</given-names></name> <name><surname>Zangrandi</surname><given-names>L.</given-names></name> <name><surname>Schwarzer</surname><given-names>C.</given-names></name> <name><surname>Gnaiger</surname><given-names>E.</given-names></name></person-group> (<year>2015</year>). <article-title>Differences in mitochondrial function in homogenated samples from healthy and epileptic specific brain tissues revealed by high-resolution respirometry</article-title>. <source>Mitochondrion</source> <volume>25</volume>, <fpage>104</fpage>&#x2013;<lpage>112</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.mito.2015.10.007</pub-id>, PMID: <pub-id pub-id-type="pmid">26516105</pub-id></mixed-citation></ref>
<ref id="ref16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buttgereit</surname><given-names>F.</given-names></name> <name><surname>Brand</surname><given-names>M. D.</given-names></name></person-group> (<year>1995</year>). <article-title>A hierarchy of ATP-consuming processes in mammalian-cells</article-title>. <source>Biochem. J.</source> <volume>312</volume>, <fpage>163</fpage>&#x2013;<lpage>167</lpage>. doi: <pub-id pub-id-type="doi">10.1042/bj3120163</pub-id></mixed-citation></ref>
<ref id="ref17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carreau</surname><given-names>A.</given-names></name> <name><surname>El Hafny-Rahbi</surname><given-names>B.</given-names></name> <name><surname>Matejuk</surname><given-names>A.</given-names></name> <name><surname>Grillon</surname><given-names>C.</given-names></name> <name><surname>Kieda</surname><given-names>C.</given-names></name></person-group> (<year>2011</year>). <article-title>Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia</article-title>. <source>J. Cell. Mol. Med.</source> <volume>15</volume>, <fpage>1239</fpage>&#x2013;<lpage>1253</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1582-4934.2011.01258.x</pub-id>, PMID: <pub-id pub-id-type="pmid">21251211</pub-id></mixed-citation></ref>
<ref id="ref18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandel</surname><given-names>N. S.</given-names></name> <name><surname>Mcclintock</surname><given-names>D. S.</given-names></name> <name><surname>Feliciano</surname><given-names>C. E.</given-names></name> <name><surname>Wood</surname><given-names>T. M.</given-names></name> <name><surname>Melendez</surname><given-names>J. A.</given-names></name> <name><surname>Rodriguez</surname><given-names>A. M.</given-names></name> <etal/></person-group>. (<year>2000</year>). <article-title>Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1 alpha during hypoxia - a mechanism of O-2 sensing</article-title>. <source>J. Biol. Chem.</source> <volume>275</volume>, <fpage>25130</fpage>&#x2013;<lpage>25138</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M001914200</pub-id>, PMID: <pub-id pub-id-type="pmid">10833514</pub-id></mixed-citation></ref>
<ref id="ref19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheignon</surname><given-names>C.</given-names></name> <name><surname>Tomas</surname><given-names>M.</given-names></name> <name><surname>Bonnefont-Rousselot</surname><given-names>D.</given-names></name> <name><surname>Faller</surname><given-names>P.</given-names></name> <name><surname>Hureau</surname><given-names>C.</given-names></name> <name><surname>Collin</surname><given-names>F.</given-names></name></person-group> (<year>2018</year>). <article-title>Oxidative stress and the amyloid beta peptide in Alzheimer's disease</article-title>. <source>Redox Biol.</source> <volume>14</volume>, <fpage>450</fpage>&#x2013;<lpage>464</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.redox.2017.10.014</pub-id>, PMID: <pub-id pub-id-type="pmid">29080524</pub-id></mixed-citation></ref>
<ref id="ref20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z.</given-names></name> <name><surname>Brodie</surname><given-names>M. J.</given-names></name> <name><surname>Liew</surname><given-names>D.</given-names></name> <name><surname>Kwan</surname><given-names>P.</given-names></name></person-group> (<year>2018</year>). <article-title>Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study</article-title>. <source>JAMA Neurol.</source> <volume>75</volume>, <fpage>279</fpage>&#x2013;<lpage>286</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamaneurol.2017.3949</pub-id>, PMID: <pub-id pub-id-type="pmid">29279892</pub-id></mixed-citation></ref>
<ref id="ref21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curia</surname><given-names>G.</given-names></name> <name><surname>Lucchi</surname><given-names>C.</given-names></name> <name><surname>Vinet</surname><given-names>J.</given-names></name> <name><surname>Gualtieri</surname><given-names>F.</given-names></name> <name><surname>Marinelli</surname><given-names>C.</given-names></name> <name><surname>Torsello</surname><given-names>A.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Pathophysiogenesis of mesial temporal lobe epilepsy: is prevention of damage antiepileptogenic?</article-title> <source>Curr. Med. Chem.</source> <volume>21</volume>, <fpage>663</fpage>&#x2013;<lpage>688</lpage>. doi: <pub-id pub-id-type="doi">10.2174/0929867320666131119152201</pub-id>, PMID: <pub-id pub-id-type="pmid">24251566</pub-id></mixed-citation></ref>
<ref id="ref22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahl</surname><given-names>N. A.</given-names></name> <name><surname>Balfour</surname><given-names>W. M.</given-names></name></person-group> (<year>1964</year>). <article-title>Prolonged anoxic survival due to anoxia pre-exposure - brain ATP lactate and pyruvate</article-title>. <source>Am. J. Phys.</source> <volume>207</volume>, <fpage>452</fpage>&#x2013;<lpage>456</lpage>. doi: <pub-id pub-id-type="doi">10.1152/ajplegacy.1964.207.2.452</pub-id></mixed-citation></ref>
<ref id="ref23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Dotto</surname><given-names>V.</given-names></name> <name><surname>Mishra</surname><given-names>P.</given-names></name> <name><surname>Vidoni</surname><given-names>S.</given-names></name> <name><surname>Fogazza</surname><given-names>M.</given-names></name> <name><surname>Maresca</surname><given-names>A.</given-names></name> <name><surname>Caporali</surname><given-names>L.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>OPA1 isoforms in the hierarchical organization of mitochondrial functions</article-title>. <source>Cell Rep.</source> <volume>19</volume>, <fpage>2557</fpage>&#x2013;<lpage>2571</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.celrep.2017.05.073</pub-id>, PMID: <pub-id pub-id-type="pmid">28636943</pub-id></mixed-citation></ref>
<ref id="ref24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diebold</surname><given-names>L.</given-names></name> <name><surname>Chandel</surname><given-names>N. S.</given-names></name></person-group> (<year>2016</year>). <article-title>Mitochondrial ROS regulation of proliferating cells</article-title>. <source>Free Radic. Biol. Med.</source> <volume>100</volume>, <fpage>86</fpage>&#x2013;<lpage>93</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2016.04.198</pub-id>, PMID: <pub-id pub-id-type="pmid">27154978</pub-id></mixed-citation></ref>
<ref id="ref25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doerrier</surname><given-names>C.</given-names></name> <name><surname>Garcia-Souza</surname><given-names>L. F.</given-names></name> <name><surname>Krumschnabel</surname><given-names>G.</given-names></name> <name><surname>Wohlfarter</surname><given-names>Y.</given-names></name> <name><surname>Meszaros</surname><given-names>A. T.</given-names></name> <name><surname>Gnaiger</surname><given-names>E.</given-names></name></person-group> (<year>2018</year>). <article-title>High-resolution fluoRespirometry and OXPHOS protocols for human cells, permeabilized fibers from small biopsies of muscle, and isolated mitochondria</article-title>. <source>Methods Mol. Biol.</source> <volume>1782</volume>, <fpage>31</fpage>&#x2013;<lpage>70</lpage>. doi: <pub-id pub-id-type="doi">10.1007/978-1-4939-7831-1_3</pub-id>, PMID: <pub-id pub-id-type="pmid">29850993</pub-id></mixed-citation></ref>
<ref id="ref26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donnelly</surname><given-names>C.</given-names></name> <name><surname>Schmitt</surname><given-names>S.</given-names></name> <name><surname>Cecatto</surname><given-names>C.</given-names></name> <name><surname>Cardoso</surname><given-names>L.</given-names></name> <name><surname>Koml&#x00F3;di</surname><given-names>T.</given-names></name> <name><surname>Place</surname><given-names>N.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>The ABC of hypoxia &#x2013; what is the norm</article-title>. <source>Bioenerg. Commun.</source> doi: <pub-id pub-id-type="doi">10.26124/mitofit:2022-0025.v2</pub-id></mixed-citation></ref>
<ref id="ref27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emerson</surname><given-names>M. R.</given-names></name> <name><surname>Nelson</surname><given-names>S. R.</given-names></name> <name><surname>Samson</surname><given-names>F. E.</given-names></name> <name><surname>Pazdernik</surname><given-names>T. L.</given-names></name></person-group> (<year>1999</year>). <article-title>Hypoxia preconditioning attenuates brain edema associated with kainic acid-induced status epilepticus in rats</article-title>. <source>Brain Res.</source> <volume>825</volume>, <fpage>189</fpage>&#x2013;<lpage>193</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s0006-8993(99)01195-6</pub-id>, PMID: <pub-id pub-id-type="pmid">10216187</pub-id></mixed-citation></ref>
<ref id="ref28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>R. S.</given-names></name> <name><surname>Acevedo</surname><given-names>C.</given-names></name> <name><surname>Arzimanoglou</surname><given-names>A.</given-names></name> <name><surname>Bogacz</surname><given-names>A.</given-names></name> <name><surname>Cross</surname><given-names>J. H.</given-names></name> <name><surname>Elger</surname><given-names>C. E.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>ILAE official report: a practical clinical definition of epilepsy</article-title>. <source>Epilepsia</source> <volume>55</volume>, <fpage>475</fpage>&#x2013;<lpage>482</lpage>. doi: <pub-id pub-id-type="doi">10.1111/epi.12550</pub-id></mixed-citation></ref>
<ref id="ref29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frezza</surname><given-names>C.</given-names></name> <name><surname>Cipolat</surname><given-names>S.</given-names></name> <name><surname>Martins De Brito</surname><given-names>O.</given-names></name> <name><surname>Micaroni</surname><given-names>M.</given-names></name> <name><surname>Beznoussenko</surname><given-names>G. V.</given-names></name> <name><surname>Rudka</surname><given-names>T.</given-names></name> <etal/></person-group>. (<year>2006</year>). <article-title>OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion</article-title>. <source>Cell</source> <volume>126</volume>, <fpage>177</fpage>&#x2013;<lpage>189</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2006.06.025</pub-id>, PMID: <pub-id pub-id-type="pmid">16839885</pub-id></mixed-citation></ref>
<ref id="ref30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fryer</surname><given-names>R. M.</given-names></name> <name><surname>Patel</surname><given-names>H. H.</given-names></name> <name><surname>Hsu</surname><given-names>A. K.</given-names></name> <name><surname>Gross</surname><given-names>G. J.</given-names></name></person-group> (<year>2001</year>). <article-title>Stress-activated protein kinase phosphorylation during cardioprotection in the ischemic myocardium</article-title>. <source>Am. J. Physiol. Heart Circ. Physiol.</source> <volume>281</volume>, <fpage>H1184</fpage>&#x2013;<lpage>H1192</lpage>. doi: <pub-id pub-id-type="doi">10.1152/ajpheart.2001.281.3.H1184</pub-id></mixed-citation></ref>
<ref id="ref31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>C. J.</given-names></name> <name><surname>Niu</surname><given-names>L.</given-names></name> <name><surname>Ren</surname><given-names>P. C.</given-names></name> <name><surname>Wang</surname><given-names>W.</given-names></name> <name><surname>Zhu</surname><given-names>C.</given-names></name> <name><surname>Li</surname><given-names>Y. Q.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Hypoxic preconditioning attenuates global cerebral ischemic injury following asphyxial cardiac arrest through regulation of delta opioid receptor system</article-title>. <source>Neuroscience</source> <volume>202</volume>, <fpage>352</fpage>&#x2013;<lpage>362</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuroscience.2011.11.060</pub-id>, PMID: <pub-id pub-id-type="pmid">22200548</pub-id></mixed-citation></ref>
<ref id="ref32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>C.</given-names></name> <name><surname>Wang</surname><given-names>C.</given-names></name> <name><surname>Liu</surname><given-names>B.</given-names></name> <name><surname>Wu</surname><given-names>H.</given-names></name> <name><surname>Yang</surname><given-names>Q. L.</given-names></name> <name><surname>Jin</surname><given-names>J. G.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Intermittent hypoxia preconditioning-induced epileptic tolerance by upregulation of monocarboxylate transporter 4 expression in rat hippocampal astrocytes</article-title>. <source>Neurochem. Res.</source> <volume>39</volume>, <fpage>2160</fpage>&#x2013;<lpage>2169</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11064-014-1411-2</pub-id>, PMID: <pub-id pub-id-type="pmid">25146899</pub-id></mixed-citation></ref>
<ref id="ref33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibbs</surname><given-names>E. T.</given-names></name> <name><surname>Lerner</surname><given-names>C. A.</given-names></name> <name><surname>Watson</surname><given-names>M. A.</given-names></name> <name><surname>Wong</surname><given-names>H. S.</given-names></name> <name><surname>Gerencser</surname><given-names>A. A.</given-names></name> <name><surname>Brand</surname><given-names>M. D.</given-names></name></person-group> (<year>2023</year>). <article-title>Site IQ in mitochondrial complex I generates S1QEL-sensitive superoxide/hydrogen peroxide in both the reverse and forward reactions</article-title>. <source>Biochem. J.</source> <volume>480</volume>, <fpage>363</fpage>&#x2013;<lpage>384</lpage>. doi: <pub-id pub-id-type="doi">10.1042/BCJ20220611</pub-id>, PMID: <pub-id pub-id-type="pmid">36862427</pub-id></mixed-citation></ref>
<ref id="ref34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gnaiger</surname><given-names>E.</given-names></name></person-group> (<year>1993</year>). <article-title>Nonequilibrium thermodynamics of energy transformations</article-title>. <source>Pure Appl. Chem.</source> <volume>65</volume>, <fpage>1983</fpage>&#x2013;<lpage>2002</lpage>. doi: <pub-id pub-id-type="doi">10.1351/pac199365091983</pub-id></mixed-citation></ref>
<ref id="ref35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gnaiger</surname><given-names>E.</given-names></name></person-group> (<year>2020</year>). <article-title>Mitochondrial pathways and respiratory control: an introduction to OXPHOS analysis</article-title>. <source>Bioenerg. Commun.</source> <fpage>1</fpage>&#x2013;<lpage>114</lpage>. doi: <pub-id pub-id-type="doi">10.26124/bec:2020-0001.v1</pub-id></mixed-citation></ref>
<ref id="ref36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gnaiger</surname><given-names>E.</given-names></name> <name><surname>Aasander Frostner</surname><given-names>E.</given-names></name> <name><surname>Abdul</surname><given-names>K.</given-names></name> <name><surname>Abdel-Rahman</surname><given-names>E.</given-names></name> <name><surname>Abumrad</surname><given-names>N.</given-names></name> <name><surname>Acuna-Castroviejo</surname><given-names>D.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Mitochondrial physiology</article-title>. <source>Bioenerg. Commun.</source>:<fpage>2020.1</fpage>.</mixed-citation></ref>
<ref id="ref37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorenkova</surname><given-names>N.</given-names></name> <name><surname>Robinson</surname><given-names>E.</given-names></name> <name><surname>Grieve</surname><given-names>D. J.</given-names></name> <name><surname>Galkin</surname><given-names>A.</given-names></name></person-group> (<year>2013</year>). <article-title>Conformational change of mitochondrial complex i increases ROS sensitivity during ischemia</article-title>. <source>Antioxid. Redox Signal.</source> <volume>19</volume>, <fpage>1459</fpage>&#x2013;<lpage>1468</lpage>. doi: <pub-id pub-id-type="doi">10.1089/ars.2012.4698</pub-id></mixed-citation></ref>
<ref id="ref38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guzy</surname><given-names>R. D.</given-names></name> <name><surname>Hoyos</surname><given-names>B.</given-names></name> <name><surname>Robin</surname><given-names>E.</given-names></name> <name><surname>Chen</surname><given-names>H.</given-names></name> <name><surname>Liu</surname><given-names>L. P.</given-names></name> <name><surname>Mansfield</surname><given-names>K. D.</given-names></name> <etal/></person-group>. (<year>2005</year>). <article-title>Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing</article-title>. <source>Cell Metab.</source> <volume>1</volume>, <fpage>401</fpage>&#x2013;<lpage>408</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cmet.2005.05.001</pub-id>, PMID: <pub-id pub-id-type="pmid">16054089</pub-id></mixed-citation></ref>
<ref id="ref39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadanny</surname><given-names>A.</given-names></name> <name><surname>Efrati</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>The hyperoxic-hypoxic paradox</article-title>. <source>Biomolecules</source> <volume>10</volume>:<fpage>958</fpage>. doi: <pub-id pub-id-type="doi">10.3390/biom10060958</pub-id>, PMID: <pub-id pub-id-type="pmid">32630465</pub-id></mixed-citation></ref>
<ref id="ref40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoehne</surname><given-names>M. N.</given-names></name> <name><surname>Jacobs</surname><given-names>L. J. H. C.</given-names></name> <name><surname>Lapacz</surname><given-names>K. J.</given-names></name> <name><surname>Calabrese</surname><given-names>G.</given-names></name> <name><surname>Murschall</surname><given-names>L. M.</given-names></name> <name><surname>Marker</surname><given-names>T.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Spatial and temporal control of mitochondrial H<sub>2</sub>O<sub>2</sub> release in intact human cells</article-title>. <source>EMBO J.</source> <volume>41</volume>:<fpage>e109169</fpage>. doi: <pub-id pub-id-type="doi">10.15252/embj.2021109169</pub-id>, PMID: <pub-id pub-id-type="pmid">35146782</pub-id></mixed-citation></ref>
<ref id="ref41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>P.</given-names></name> <name><surname>Kuo</surname><given-names>C. Y.</given-names></name> <name><surname>Cheng</surname><given-names>C. T.</given-names></name> <name><surname>Liou</surname><given-names>J. P.</given-names></name> <name><surname>Ann</surname><given-names>D. K.</given-names></name> <name><surname>Chen</surname><given-names>Q.</given-names></name></person-group> (<year>2014</year>). <article-title>Intermediary metabolite precursor dimethyl-2-ketoglutarate stabilizes hypoxia-inducible factor-1alpha by inhibiting prolyl-4-hydroxylase PHD2</article-title>. <source>PLoS One</source> <volume>9</volume>:<fpage>e113865</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0113865</pub-id>, PMID: <pub-id pub-id-type="pmid">25420025</pub-id></mixed-citation></ref>
<ref id="ref42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirino</surname><given-names>T.</given-names></name></person-group> (<year>2002</year>). <article-title>Ischemic tolerance</article-title>. <source>J. Cereb. Blood Flow Metab.</source> <volume>22</volume>, <fpage>1283</fpage>&#x2013;<lpage>1296</lpage>. doi: <pub-id pub-id-type="doi">10.1097/01.WCB.0000040942.89393.88</pub-id>, PMID: <pub-id pub-id-type="pmid">12439285</pub-id></mixed-citation></ref>
<ref id="ref43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koml&#x00F3;di</surname><given-names>T.</given-names></name> <name><surname>Geibl</surname><given-names>F. F.</given-names></name> <name><surname>Sassani</surname><given-names>M.</given-names></name> <name><surname>Ambrus</surname><given-names>A.</given-names></name> <name><surname>Tretter</surname><given-names>L.</given-names></name></person-group> (<year>2018a</year>). <article-title>Membrane potential and delta pH dependency of reverse electron transport-associated hydrogen peroxide production in brain and heart mitochondria</article-title>. <source>J. Bioenerg. Biomembr.</source> <volume>50</volume>, <fpage>355</fpage>&#x2013;<lpage>365</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10863-018-9766-8</pub-id>, PMID: <pub-id pub-id-type="pmid">30116920</pub-id></mixed-citation></ref>
<ref id="ref44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komlodi</surname><given-names>T.</given-names></name> <name><surname>Sobotka</surname><given-names>O.</given-names></name> <name><surname>Gnaiger</surname><given-names>E.</given-names></name></person-group> (<year>2021</year>). <article-title>Facts and artefacts on the oxygen dependence of hydrogen peroxide production using Amplex UltraRed</article-title>. <source>Bioenerg. Commun.</source> doi: <pub-id pub-id-type="doi">10.26124/bec:2021-0004</pub-id></mixed-citation></ref>
<ref id="ref45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koml&#x00F3;di</surname><given-names>T.</given-names></name> <name><surname>Sobotka</surname><given-names>O.</given-names></name> <name><surname>Krumschnabel</surname><given-names>G.</given-names></name> <name><surname>Bezuidenhout</surname><given-names>N.</given-names></name> <name><surname>Hiller</surname><given-names>E.</given-names></name> <name><surname>Doerrier</surname><given-names>C.</given-names></name> <etal/></person-group>. (<year>2018b</year>). <article-title>Comparison of mitochondrial incubation Media for Measurement of respiration and hydrogen peroxide production</article-title>. <source>Methods Mol. Biol.</source> <volume>1782</volume>, <fpage>137</fpage>&#x2013;<lpage>155</lpage>. doi: <pub-id pub-id-type="doi">10.1007/978-1-4939-7831-1_8</pub-id>, PMID: <pub-id pub-id-type="pmid">29850998</pub-id></mixed-citation></ref>
<ref id="ref46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kopp</surname><given-names>S. J.</given-names></name> <name><surname>Krieglstein</surname><given-names>J.</given-names></name> <name><surname>Freidank</surname><given-names>A.</given-names></name> <name><surname>Rachman</surname><given-names>A.</given-names></name> <name><surname>Seibert</surname><given-names>A.</given-names></name> <name><surname>Cohen</surname><given-names>M. M.</given-names></name></person-group> (<year>1984</year>). <article-title>P-31 nuclear magnetic resonance analysis of brain: II. Effects of oxygen deprivation on isolated perfused and nonperfused rat brain</article-title>. <source>J. Neurochem.</source> <volume>43</volume>, <fpage>1716</fpage>&#x2013;<lpage>1731</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1471-4159.1984.tb06100.x</pub-id>, PMID: <pub-id pub-id-type="pmid">6092545</pub-id></mixed-citation></ref>
<ref id="ref47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kudin</surname><given-names>A. P.</given-names></name> <name><surname>Kudina</surname><given-names>T. A.</given-names></name> <name><surname>Seyfried</surname><given-names>J.</given-names></name> <name><surname>Vielhaber</surname><given-names>S.</given-names></name> <name><surname>Beck</surname><given-names>H.</given-names></name> <name><surname>Elger</surname><given-names>C. E.</given-names></name> <etal/></person-group>. (<year>2002</year>). <article-title>Seizure-dependent modulation of mitochondrial oxidative phosphorylation in rat hippocampus</article-title>. <source>Eur. J. Neurosci.</source> <volume>15</volume>, <fpage>1105</fpage>&#x2013;<lpage>1114</lpage>. doi: <pub-id pub-id-type="doi">10.1046/j.1460-9568.2002.01947.x</pub-id>, PMID: <pub-id pub-id-type="pmid">11982622</pub-id></mixed-citation></ref>
<ref id="ref48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lebuffe</surname><given-names>G.</given-names></name> <name><surname>Schumacker</surname><given-names>P. T.</given-names></name> <name><surname>Shao</surname><given-names>Z. H.</given-names></name> <name><surname>Anderson</surname><given-names>T.</given-names></name> <name><surname>Iwase</surname><given-names>H.</given-names></name> <name><surname>Vanden Hoek</surname><given-names>T. L.</given-names></name></person-group> (<year>2003</year>). <article-title>ROS and NO trigger early preconditioning: relationship to mitochondrial KATP channel</article-title>. <source>Am. J. Physiol. Heart Circ. Physiol.</source> <volume>284</volume>, <fpage>H299</fpage>&#x2013;<lpage>H308</lpage>. doi: <pub-id pub-id-type="doi">10.1152/ajpheart.00706.2002</pub-id></mixed-citation></ref>
<ref id="ref49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>P.</given-names></name> <name><surname>Chandel</surname><given-names>N. S.</given-names></name> <name><surname>Simon</surname><given-names>M. C.</given-names></name></person-group> (<year>2020</year>). <article-title>Cellular adaptation to hypoxia through hypoxia inducible factors and beyond</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source> <volume>21</volume>, <fpage>268</fpage>&#x2013;<lpage>283</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41580-020-0227-y</pub-id>, PMID: <pub-id pub-id-type="pmid">32144406</pub-id></mixed-citation></ref>
<ref id="ref50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S. J.</given-names></name> <name><surname>Hafeez</surname><given-names>A.</given-names></name> <name><surname>Noorulla</surname><given-names>F.</given-names></name> <name><surname>Geng</surname><given-names>X. K.</given-names></name> <name><surname>Shao</surname><given-names>G.</given-names></name> <name><surname>Ren</surname><given-names>C. H.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Preconditioning in neuroprotection: from hypoxia to ischemia</article-title>. <source>Prog. Neurobiol.</source> <volume>157</volume>, <fpage>79</fpage>&#x2013;<lpage>91</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.pneurobio.2017.01.001</pub-id>, PMID: <pub-id pub-id-type="pmid">28110083</pub-id></mixed-citation></ref>
<ref id="ref51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name> <name><surname>Gu</surname><given-names>Y. K.</given-names></name> <name><surname>Guo</surname><given-names>M. Y.</given-names></name> <name><surname>Ji</surname><given-names>X. M.</given-names></name></person-group> (<year>2021</year>). <article-title>Neuroprotective effects and mechanisms of ischemic/hypoxic preconditioning on neurological diseases</article-title>. <source>CNS Neurosci. Ther.</source> <volume>27</volume>, <fpage>869</fpage>&#x2013;<lpage>882</lpage>. doi: <pub-id pub-id-type="doi">10.1111/cns.13642</pub-id>, PMID: <pub-id pub-id-type="pmid">34237192</pub-id></mixed-citation></ref>
<ref id="ref52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name> <name><surname>Narasimhan</surname><given-names>P.</given-names></name> <name><surname>Yu</surname><given-names>F.</given-names></name> <name><surname>Chan</surname><given-names>P. H.</given-names></name></person-group> (<year>2005</year>). <article-title>Neuroprotection by hypoxic preconditioning involves oxidative stress-mediated expression of hypoxia-inducible factor and erythropoietin</article-title>. <source>Stroke</source> <volume>36</volume>, <fpage>1264</fpage>&#x2013;<lpage>1269</lpage>. doi: <pub-id pub-id-type="doi">10.1161/01.STR.0000166180.91042.02</pub-id>, PMID: <pub-id pub-id-type="pmid">15890996</pub-id></mixed-citation></ref>
<ref id="ref53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>H. Z.</given-names></name> <name><surname>Cheng</surname><given-names>Y.</given-names></name> <name><surname>Zhou</surname><given-names>Z. W.</given-names></name> <name><surname>Luo</surname><given-names>H. Y.</given-names></name> <name><surname>Wen</surname><given-names>D. D.</given-names></name> <name><surname>Gao</surname><given-names>L. C.</given-names></name></person-group> (<year>2021</year>). <article-title>PI3K/AKT signal pathway: a target of natural products in the prevention and treatment of Alzheimer's disease and Parkinson's disease</article-title>. <source>Front. Pharmacol.</source> <volume>12</volume>:<fpage>648636</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fphar.2021.648636</pub-id>, PMID: <pub-id pub-id-type="pmid">33935751</pub-id></mixed-citation></ref>
<ref id="ref54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macdonald</surname><given-names>P. J.</given-names></name> <name><surname>Francy</surname><given-names>C. A.</given-names></name> <name><surname>Stepanyants</surname><given-names>N.</given-names></name> <name><surname>Lehman</surname><given-names>L.</given-names></name> <name><surname>Baglio</surname><given-names>A.</given-names></name> <name><surname>Mears</surname><given-names>J. A.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Distinct splice variants of dynamin-related protein 1 differentially utilize mitochondrial fission factor as an effector of cooperative GTPase activity</article-title>. <source>J. Biol. Chem.</source> <volume>291</volume>, <fpage>493</fpage>&#x2013;<lpage>507</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M115.680181</pub-id></mixed-citation></ref>
<ref id="ref55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malinska</surname><given-names>D.</given-names></name> <name><surname>Mirandola</surname><given-names>S. R.</given-names></name> <name><surname>Kunz</surname><given-names>W. S.</given-names></name></person-group> (<year>2010</year>). <article-title>Mitochondrial potassium channels and reactive oxygen species</article-title>. <source>FEBS Lett.</source> <volume>584</volume>, <fpage>2043</fpage>&#x2013;<lpage>2048</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.febslet.2010.01.013</pub-id>, PMID: <pub-id pub-id-type="pmid">20080090</pub-id></mixed-citation></ref>
<ref id="ref56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuda</surname><given-names>T.</given-names></name> <name><surname>Shimizu</surname><given-names>I.</given-names></name> <name><surname>Murata</surname><given-names>Y.</given-names></name> <name><surname>Baba</surname><given-names>A.</given-names></name></person-group> (<year>1992</year>). <article-title>Glucose and oxygen deprivation induces a Ca(2+)- mediated decrease in (Na(+)+K+)- Atpase activity in rat-brain slices</article-title>. <source>Brain Res.</source> <volume>576</volume>, <fpage>263</fpage>&#x2013;<lpage>270</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0006-8993(92)90689-7</pub-id>, PMID: <pub-id pub-id-type="pmid">1387578</pub-id></mixed-citation></ref>
<ref id="ref57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mink</surname><given-names>J. W.</given-names></name> <name><surname>Blumenschine</surname><given-names>R. J.</given-names></name> <name><surname>Adams</surname><given-names>D. B.</given-names></name></person-group> (<year>1981</year>). <article-title>Ratio of central nervous system to body metabolism in vertebrates: its constancy and functional basis</article-title>. <source>Am. J. Phys.</source> <volume>241</volume>, <fpage>R203</fpage>&#x2013;<lpage>R212</lpage>. doi: <pub-id pub-id-type="doi">10.1152/ajpregu.1981.241.3.R203</pub-id></mixed-citation></ref>
<ref id="ref58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>F. L.</given-names></name> <name><surname>Liu</surname><given-names>Y. H.</given-names></name> <name><surname>VAN Remmen</surname><given-names>H.</given-names></name></person-group> (<year>2004</year>). <article-title>Complex III releases superoxide to both sides of the inner mitochondrial membrane</article-title>. <source>J. Biol. Chem.</source> <volume>279</volume>, <fpage>49064</fpage>&#x2013;<lpage>49073</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M407715200</pub-id></mixed-citation></ref>
<ref id="ref59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murali Mahadevan</surname><given-names>H.</given-names></name> <name><surname>Hashemiaghdam</surname><given-names>A.</given-names></name> <name><surname>Ashrafi</surname><given-names>G.</given-names></name> <name><surname>Harbauer</surname><given-names>A. B.</given-names></name></person-group> (<year>2021</year>). <article-title>Mitochondria in neuronal health: from energy metabolism to Parkinson's disease</article-title>. <source>Adv. Biol. (Weinh)</source> <volume>5</volume>:<fpage>e2100663</fpage>. doi: <pub-id pub-id-type="doi">10.1002/adbi.202100663</pub-id>, PMID: <pub-id pub-id-type="pmid">34382382</pub-id></mixed-citation></ref>
<ref id="ref60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olichon</surname><given-names>A.</given-names></name> <name><surname>Baricault</surname><given-names>L.</given-names></name> <name><surname>Gas</surname><given-names>N.</given-names></name> <name><surname>Guillou</surname><given-names>E.</given-names></name> <name><surname>Valette</surname><given-names>A.</given-names></name> <name><surname>Belenguer</surname><given-names>P.</given-names></name> <etal/></person-group>. (<year>2003</year>). <article-title>Loss of OPA1 perturbates the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis</article-title>. <source>J. Biol. Chem.</source> <volume>278</volume>, <fpage>7743</fpage>&#x2013;<lpage>7746</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.C200677200</pub-id>, PMID: <pub-id pub-id-type="pmid">12509422</pub-id></mixed-citation></ref>
<ref id="ref61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olowe</surname><given-names>R.</given-names></name> <name><surname>Sandouka</surname><given-names>S.</given-names></name> <name><surname>Saadi</surname><given-names>A.</given-names></name> <name><surname>Shekh-Ahmad</surname><given-names>T.</given-names></name></person-group> (<year>2020</year>). <article-title>Approaches for reactive oxygen species and oxidative stress quantification in epilepsy</article-title>. <source>Antioxidants</source> <volume>9</volume>:<fpage>990</fpage>. doi: <pub-id pub-id-type="doi">10.3390/antiox9100990</pub-id>, PMID: <pub-id pub-id-type="pmid">33066477</pub-id></mixed-citation></ref>
<ref id="ref62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostrowski</surname><given-names>R. P.</given-names></name> <name><surname>Zhang</surname><given-names>J. H.</given-names></name></person-group> (<year>2020</year>). <article-title>The insights into molecular pathways of hypoxia-inducible factor in the brain</article-title>. <source>J. Neurosci. Res.</source> <volume>98</volume>, <fpage>57</fpage>&#x2013;<lpage>76</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jnr.24366</pub-id>, PMID: <pub-id pub-id-type="pmid">30548473</pub-id></mixed-citation></ref>
<ref id="ref63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>L. N.</given-names></name> <name><surname>Zhu</surname><given-names>W.</given-names></name> <name><surname>Li</surname><given-names>Y.</given-names></name> <name><surname>Xu</surname><given-names>X. L.</given-names></name> <name><surname>Guo</surname><given-names>L. J.</given-names></name> <name><surname>Lu</surname><given-names>Q.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Astrocytic toll-like receptor 3 is associated with ischemic preconditioning-induced protection against brain ischemia in rodents</article-title>. <source>PLoS One</source> <volume>9</volume>:<fpage>e99526</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0099526</pub-id>, PMID: <pub-id pub-id-type="pmid">24914679</pub-id></mixed-citation></ref>
<ref id="ref64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>Y. Y.</given-names></name> <name><surname>Nguyen</surname><given-names>O. T.</given-names></name> <name><surname>Kang</surname><given-names>H.</given-names></name> <name><surname>Cho</surname><given-names>H.</given-names></name></person-group> (<year>2014</year>). <article-title>MARCH5-mediated quality control on acetylated Mfn1 facilitates mitochondrial homeostasis and cell survival</article-title>. <source>Cell Death Dis.</source> <volume>5</volume>:<fpage>e1172</fpage>. doi: <pub-id pub-id-type="doi">10.1038/cddis.2014.142</pub-id>, PMID: <pub-id pub-id-type="pmid">24722297</pub-id></mixed-citation></ref>
<ref id="ref65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearson-Smith</surname><given-names>J. N.</given-names></name> <name><surname>Patel</surname><given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>Metabolic dysfunction and oxidative stress in epilepsy</article-title>. <source>Int. J. Mol. Sci.</source> <volume>18</volume>:<fpage>2365</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms18112365</pub-id>, PMID: <pub-id pub-id-type="pmid">29117123</pub-id></mixed-citation></ref>
<ref id="ref66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>P. B. A. A.</given-names></name></person-group> (<year>2016</year>). <article-title>Quality of life in patients with neurodegenerative diseases</article-title>. <source>J. Neurol. Neurosci.</source> <volume>7</volume>:<fpage>74</fpage>. doi: <pub-id pub-id-type="doi">10.21767/2171-6625.100074</pub-id></mixed-citation></ref>
<ref id="ref67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>A.</given-names></name></person-group> (<year>2011</year>). <article-title>The selfish brain: competition for energy resources</article-title>. <source>Am. J. Hum. Biol.</source> <volume>23</volume>, <fpage>29</fpage>&#x2013;<lpage>34</lpage>. doi: <pub-id pub-id-type="doi">10.1002/ajhb.21106</pub-id>, PMID: <pub-id pub-id-type="pmid">21080380</pub-id></mixed-citation></ref>
<ref id="ref68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pohle</surname><given-names>W.</given-names></name> <name><surname>Rauca</surname><given-names>C.</given-names></name></person-group> (<year>1994</year>). <article-title>Hypoxia protects against the neurotoxicity of kainic acid</article-title>. <source>Brain Res.</source> <volume>644</volume>, <fpage>297</fpage>&#x2013;<lpage>304</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0006-8993(94)91693-4</pub-id>, PMID: <pub-id pub-id-type="pmid">8050040</pub-id></mixed-citation></ref>
<ref id="ref69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puspita</surname><given-names>L.</given-names></name> <name><surname>Chung</surname><given-names>S. Y.</given-names></name> <name><surname>Shim</surname><given-names>J. W.</given-names></name></person-group> (<year>2017</year>). <article-title>Oxidative stress and cellular pathologies in Parkinson's disease</article-title>. <source>Mol. Brain</source> <volume>10</volume>:<fpage>53</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13041-017-0340-9</pub-id>, PMID: <pub-id pub-id-type="pmid">29183391</pub-id></mixed-citation></ref>
<ref id="ref70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>Y.</given-names></name> <name><surname>Jiang</surname><given-names>W.</given-names></name> <name><surname>Li</surname><given-names>A.</given-names></name> <name><surname>Gao</surname><given-names>M.</given-names></name> <name><surname>Liu</surname><given-names>H.</given-names></name> <name><surname>Gao</surname><given-names>Y.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>The combination of paraformaldehyde and glutaraldehyde is a potential fixative for mitochondria</article-title>. <source>Biomolecules</source> <volume>11</volume>:<fpage>711</fpage>. doi: <pub-id pub-id-type="doi">10.3390/biom11050711</pub-id>, PMID: <pub-id pub-id-type="pmid">34068806</pub-id></mixed-citation></ref>
<ref id="ref71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>C.</given-names></name> <name><surname>Yap</surname><given-names>S.</given-names></name> <name><surname>Woodman</surname><given-names>O. L.</given-names></name></person-group> (<year>2009</year>). <article-title>Antioxidants in the prevention of myocardial ischemia/reperfusion injury</article-title>. <source>Expert. Rev. Clin. Pharmacol.</source> <volume>2</volume>, <fpage>673</fpage>&#x2013;<lpage>695</lpage>. doi: <pub-id pub-id-type="doi">10.1586/ecp.09.41</pub-id>, PMID: <pub-id pub-id-type="pmid">22112260</pub-id></mixed-citation></ref>
<ref id="ref72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rambold</surname><given-names>A. S.</given-names></name> <name><surname>Kostelecky</surname><given-names>B.</given-names></name> <name><surname>Elia</surname><given-names>N.</given-names></name> <name><surname>Lippincott-Schwartz</surname><given-names>J.</given-names></name></person-group> (<year>2011</year>). <article-title>Tubular network formation protects mitochondria from autophagosomal degradation during nutrient starvation</article-title>. <source>Proc. Natl. Acad. Sci. USA</source> <volume>108</volume>, <fpage>10190</fpage>&#x2013;<lpage>10195</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1107402108</pub-id>, PMID: <pub-id pub-id-type="pmid">21646527</pub-id></mixed-citation></ref>
<ref id="ref73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rauca</surname><given-names>C.</given-names></name> <name><surname>Zerbe</surname><given-names>R.</given-names></name> <name><surname>Jantze</surname><given-names>H.</given-names></name> <name><surname>Krug</surname><given-names>M.</given-names></name></person-group> (<year>2000</year>). <article-title>The importance of free hydroxyl radicals to hypoxia preconditioning</article-title>. <source>Brain Res.</source> <volume>868</volume>, <fpage>147</fpage>&#x2013;<lpage>149</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0006-8993(00)02388-X</pub-id>, PMID: <pub-id pub-id-type="pmid">10841900</pub-id></mixed-citation></ref>
<ref id="ref74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reczek</surname><given-names>C. R.</given-names></name> <name><surname>Chandel</surname><given-names>N. S.</given-names></name></person-group> (<year>2015</year>). <article-title>ROS-dependent signal transduction</article-title>. <source>Curr. Opin. Cell Biol.</source> <volume>33</volume>, <fpage>8</fpage>&#x2013;<lpage>13</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ceb.2014.09.010</pub-id>, PMID: <pub-id pub-id-type="pmid">25305438</pub-id></mixed-citation></ref>
<ref id="ref75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redza-Dutordoir</surname><given-names>M.</given-names></name> <name><surname>Averill-Bates</surname><given-names>D. A.</given-names></name></person-group> (<year>2016</year>). <article-title>Activation of apoptosis signalling pathways by reactive oxygen species</article-title>. <source>Biochim. Biophys. Acta</source> <volume>1863</volume>, <fpage>2977</fpage>&#x2013;<lpage>2992</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbamcr.2016.09.012</pub-id>, PMID: <pub-id pub-id-type="pmid">27646922</pub-id></mixed-citation></ref>
<ref id="ref76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richard</surname><given-names>D. E.</given-names></name> <name><surname>Berra</surname><given-names>E.</given-names></name> <name><surname>Pouyssegur</surname><given-names>J.</given-names></name></person-group> (<year>2000</year>). <article-title>Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells</article-title>. <source>J. Biol. Chem.</source> <volume>275</volume>, <fpage>26765</fpage>&#x2013;<lpage>26771</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M003325200</pub-id></mixed-citation></ref>
<ref id="ref77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogatzki</surname><given-names>M. J.</given-names></name> <name><surname>Ferguson</surname><given-names>B. S.</given-names></name> <name><surname>Goodwin</surname><given-names>M. L.</given-names></name> <name><surname>Gladden</surname><given-names>L. B.</given-names></name></person-group> (<year>2015</year>). <article-title>Lactate is always the end product of glycolysis</article-title>. <source>Front. Neurosci.</source> <volume>9</volume>:<fpage>22</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnins.2015.00022</pub-id>, PMID: <pub-id pub-id-type="pmid">25774123</pub-id></mixed-citation></ref>
<ref id="ref78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubaj</surname><given-names>A.</given-names></name> <name><surname>Gustaw</surname><given-names>K.</given-names></name> <name><surname>Zgodzi&#x0144;ski</surname><given-names>W.</given-names></name> <name><surname>Kleinrok</surname><given-names>Z.</given-names></name> <name><surname>Sieklucka-Dziuba</surname><given-names>M.</given-names></name></person-group> (<year>2000</year>). <article-title>The role of opioid receptors in hypoxic preconditioning against seizures in brain</article-title>. <source>Pharmacol. Biochem. Behav.</source> <volume>67</volume>, <fpage>65</fpage>&#x2013;<lpage>70</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0091-3057(00)00294-X</pub-id></mixed-citation></ref>
<ref id="ref79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rybnikova</surname><given-names>E.</given-names></name> <name><surname>Samoilov</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>Current insights into the molecular mechanisms of hypoxic pre- and postconditioning using hypobaric hypoxia</article-title>. <source>Front. Neurosci.</source> <volume>9</volume>:<fpage>388</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnins.2015.00388</pub-id>, PMID: <pub-id pub-id-type="pmid">26557049</pub-id></mixed-citation></ref>
<ref id="ref80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanjuan-Pla</surname><given-names>A.</given-names></name> <name><surname>Cervera</surname><given-names>A. M.</given-names></name> <name><surname>Apostolova</surname><given-names>N.</given-names></name> <name><surname>Garcia-Bou</surname><given-names>R.</given-names></name> <name><surname>Victor</surname><given-names>V. M.</given-names></name> <name><surname>Murphy</surname><given-names>M. P.</given-names></name> <etal/></person-group>. (<year>2005</year>). <article-title>A targeted antioxidant reveals the importance of mitochondrial reactive oxygen species in the hypoxic signaling of HIF-1alpha</article-title>. <source>FEBS Lett.</source> <volume>579</volume>, <fpage>2669</fpage>&#x2013;<lpage>2674</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.febslet.2005.03.088</pub-id></mixed-citation></ref>
<ref id="ref81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schonenberger</surname><given-names>M. J.</given-names></name> <name><surname>Kovacs</surname><given-names>W. J.</given-names></name></person-group> (<year>2015</year>). <article-title>Hypoxia signaling pathways: modulators of oxygen-related organelles</article-title>. <source>Front. Cell Dev. Biol.</source> <volume>3</volume>:<fpage>42</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fcell.2015.00042</pub-id>, PMID: <pub-id pub-id-type="pmid">26258123</pub-id></mixed-citation></ref>
<ref id="ref82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scialo</surname><given-names>F.</given-names></name> <name><surname>Fernandez-Ayala</surname><given-names>D. J.</given-names></name> <name><surname>Sanz</surname><given-names>A.</given-names></name></person-group> (<year>2017</year>). <article-title>Role of mitochondrial reverse electron transport in ROS signaling: potential roles in health and disease</article-title>. <source>Front. Physiol.</source> <volume>8</volume>:<fpage>428</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fphys.2017.00428</pub-id>, PMID: <pub-id pub-id-type="pmid">28701960</pub-id></mixed-citation></ref>
<ref id="ref83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semenza</surname><given-names>G. L.</given-names></name></person-group> (<year>1999</year>). <article-title>Regulation of mammalian O<sub>2</sub> homeostasis by hypoxia-inducible factor 1</article-title>. <source>Annu. Rev. Cell Dev. Biol.</source> <volume>15</volume>, <fpage>551</fpage>&#x2013;<lpage>578</lpage>. doi: <pub-id pub-id-type="doi">10.1146/annurev.cellbio.15.1.551</pub-id>, PMID: <pub-id pub-id-type="pmid">10611972</pub-id></mixed-citation></ref>
<ref id="ref84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shukitt-Hale</surname><given-names>B.</given-names></name> <name><surname>Banderet</surname><given-names>L. E.</given-names></name> <name><surname>Lieberman</surname><given-names>H. R.</given-names></name></person-group> (<year>1998</year>). <article-title>Elevation-dependent symptom, mood, and performance changes produced by exposure to hypobaric hypoxia</article-title>. <source>Int. J. Aviat. Psychol.</source> <volume>8</volume>, <fpage>319</fpage>&#x2013;<lpage>334</lpage>. doi: <pub-id pub-id-type="doi">10.1207/s15327108ijap0804_1</pub-id>, PMID: <pub-id pub-id-type="pmid">11542275</pub-id></mixed-citation></ref>
<ref id="ref85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sies</surname><given-names>H.</given-names></name></person-group> (<year>2015</year>). <article-title>Oxidative stress: a concept in redox biology and medicine</article-title>. <source>Redox Biol.</source> <volume>4</volume>:<fpage>180-3</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.redox.2015.01.002</pub-id>, PMID: <pub-id pub-id-type="pmid">25588755</pub-id></mixed-citation></ref>
<ref id="ref001"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sies</surname><given-names>H.</given-names></name></person-group> (<year>2020</year>). <article-title>Findings in redox biology: From H<sub>2</sub>O<sub>2</sub> to oxidative stress</article-title>. <source>J. Biol. Chem.</source> <volume>295</volume>, <fpage>13458</fpage>&#x2013;<lpage>13473</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.X120.015651</pub-id>, PMID: <pub-id pub-id-type="pmid">25588755</pub-id></mixed-citation></ref>
<ref id="ref86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sies</surname><given-names>H.</given-names></name> <name><surname>Jones</surname><given-names>D. P.</given-names></name></person-group> (<year>2020</year>). <article-title>Reactive oxygen species (ROS) as pleiotropic physiological signalling agents</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source> <volume>21</volume>, <fpage>363</fpage>&#x2013;<lpage>383</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41580-020-0230-3</pub-id>, PMID: <pub-id pub-id-type="pmid">32231263</pub-id></mixed-citation></ref>
<ref id="ref87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>R. A. D.</given-names></name> <name><surname>Peixoto-Santos</surname><given-names>J. E.</given-names></name> <name><surname>Scandiuzzi</surname><given-names>R. C.</given-names></name> <name><surname>Balista</surname><given-names>P. A.</given-names></name> <name><surname>Bassi</surname><given-names>M.</given-names></name> <name><surname>Glass</surname><given-names>M. L.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Decreased neuron loss and memory dysfunction in pilocarpine-treated rats pre-exposed to hypoxia</article-title>. <source>Neuroscience</source> <volume>332</volume>, <fpage>88</fpage>&#x2013;<lpage>100</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuroscience.2016.06.047</pub-id></mixed-citation></ref>
<ref id="ref88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silver</surname><given-names>I.</given-names></name> <name><surname>Erecinska</surname><given-names>M.</given-names></name></person-group> (<year>1998</year>). <article-title>Oxygen and ion concentrations in normoxic and hypoxic brain cells</article-title>. <source>Adv. Exp. Med. Biol.</source> <volume>454</volume>, <fpage>7</fpage>&#x2013;<lpage>16</lpage>. doi: <pub-id pub-id-type="doi">10.1007/978-1-4615-4863-8_2</pub-id></mixed-citation></ref>
<ref id="ref89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinenko</surname><given-names>S. A.</given-names></name> <name><surname>Starkova</surname><given-names>T. Y.</given-names></name> <name><surname>Kuzmin</surname><given-names>A. A.</given-names></name> <name><surname>Tomilin</surname><given-names>A. N.</given-names></name></person-group> (<year>2021</year>). <article-title>Physiological signaling functions of reactive oxygen species in stem cells: from flies to man</article-title>. <source>Front. Cell Dev. Biol.</source> <volume>9</volume>:<fpage>714370</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fcell.2021.714370</pub-id>, PMID: <pub-id pub-id-type="pmid">34422833</pub-id></mixed-citation></ref>
<ref id="ref90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stetler</surname><given-names>R. A.</given-names></name> <name><surname>Leak</surname><given-names>R. K.</given-names></name> <name><surname>Gan</surname><given-names>Y.</given-names></name> <name><surname>Li</surname><given-names>P. Y.</given-names></name> <name><surname>Zhang</surname><given-names>F.</given-names></name> <name><surname>Hu</surname><given-names>X. M.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Preconditioning provides neuroprotection in models of CNS disease: paradigms and clinical significance</article-title>. <source>Prog. Neurobiol.</source> <volume>114</volume>, <fpage>58</fpage>&#x2013;<lpage>83</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.pneurobio.2013.11.005</pub-id>, PMID: <pub-id pub-id-type="pmid">24389580</pub-id></mixed-citation></ref>
<ref id="ref91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tahara</surname><given-names>E. B.</given-names></name> <name><surname>Navarete</surname><given-names>F. D. T.</given-names></name> <name><surname>Kowaltowski</surname><given-names>A. J.</given-names></name></person-group> (<year>2009</year>). <article-title>Tissue-, substrate-, and site-specific characteristics of mitochondrial reactive oxygen species generation</article-title>. <source>Free Radic. Biol. Med.</source> <volume>46</volume>, <fpage>1283</fpage>&#x2013;<lpage>1297</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2009.02.008</pub-id>, PMID: <pub-id pub-id-type="pmid">19245829</pub-id></mixed-citation></ref>
<ref id="ref92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thijs</surname><given-names>R. D.</given-names></name> <name><surname>Surges</surname><given-names>R.</given-names></name> <name><surname>O'brien</surname><given-names>T. J.</given-names></name> <name><surname>Sander</surname><given-names>J. W.</given-names></name></person-group> (<year>2019</year>). <article-title>Epilepsy in adults</article-title>. <source>Lancet</source> <volume>393</volume>, <fpage>689</fpage>&#x2013;<lpage>701</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(18)32596-0</pub-id>, PMID: <pub-id pub-id-type="pmid">30686584</pub-id></mixed-citation></ref>
<ref id="ref93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>L. W.</given-names></name> <name><surname>Ashcroft</surname><given-names>M.</given-names></name></person-group> (<year>2019</year>). <article-title>Exploring the molecular interface between hypoxia-inducible factor signalling and mitochondria</article-title>. <source>Cell. Mol. Life Sci.</source> <volume>76</volume>, <fpage>1759</fpage>&#x2013;<lpage>1777</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00018-019-03039-y</pub-id>, PMID: <pub-id pub-id-type="pmid">30767037</pub-id></mixed-citation></ref>
<ref id="ref94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>J. W.</given-names></name> <name><surname>Dave</surname><given-names>K. R.</given-names></name> <name><surname>Young</surname><given-names>J. I.</given-names></name> <name><surname>Perez-Pinzon</surname><given-names>M. A.</given-names></name></person-group> (<year>2013</year>). <article-title>Ischemic preconditioning alters the epigenetic profile of the brain from ischemic intolerance to ischemic tolerance</article-title>. <source>Neurotherapeutics</source> <volume>10</volume>, <fpage>789</fpage>&#x2013;<lpage>797</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s13311-013-0202-9</pub-id>, PMID: <pub-id pub-id-type="pmid">23868468</pub-id></mixed-citation></ref>
<ref id="ref95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tilokani</surname><given-names>L.</given-names></name> <name><surname>Nagashima</surname><given-names>S.</given-names></name> <name><surname>Paupe</surname><given-names>V.</given-names></name> <name><surname>Prudent</surname><given-names>J.</given-names></name></person-group> (<year>2018</year>). <article-title>Mitochondrial dynamics: overview of molecular mechanisms</article-title>. <source>Essays Biochem.</source> <volume>62</volume>, <fpage>341</fpage>&#x2013;<lpage>360</lpage>. doi: <pub-id pub-id-type="doi">10.1042/EBC20170104</pub-id>, PMID: <pub-id pub-id-type="pmid">30030364</pub-id></mixed-citation></ref>
<ref id="ref96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tirichen</surname><given-names>H.</given-names></name> <name><surname>Yaigoub</surname><given-names>H.</given-names></name> <name><surname>Xu</surname><given-names>W. W.</given-names></name> <name><surname>Wu</surname><given-names>C. X.</given-names></name> <name><surname>Li</surname><given-names>R. S.</given-names></name> <name><surname>Li</surname><given-names>Y. F.</given-names></name></person-group> (<year>2021</year>). <article-title>Mitochondrial reactive oxygen species and their contribution in chronic kidney disease progression through oxidative stress</article-title>. <source>Front. Physiol.</source> <volume>12</volume>:<fpage>627837</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fphys.2021.627837</pub-id>, PMID: <pub-id pub-id-type="pmid">33967820</pub-id></mixed-citation></ref>
<ref id="ref97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tondera</surname><given-names>D.</given-names></name> <name><surname>Grandemange</surname><given-names>S.</given-names></name> <name><surname>Jourdain</surname><given-names>A.</given-names></name> <name><surname>Karbowski</surname><given-names>M.</given-names></name> <name><surname>Mattenberger</surname><given-names>Y.</given-names></name> <name><surname>Herzig</surname><given-names>S.</given-names></name> <etal/></person-group>. (<year>2009</year>). <article-title>SLP-2 is required for stress-induced mitochondrial hyperfusion</article-title>. <source>EMBO J.</source> <volume>28</volume>, <fpage>1589</fpage>&#x2013;<lpage>1600</lpage>. doi: <pub-id pub-id-type="doi">10.1038/emboj.2009.89</pub-id>, PMID: <pub-id pub-id-type="pmid">19360003</pub-id></mixed-citation></ref>
<ref id="ref98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turovskaya</surname><given-names>M. V.</given-names></name> <name><surname>Gaidin</surname><given-names>S. G.</given-names></name> <name><surname>Vedunova</surname><given-names>M. V.</given-names></name> <name><surname>Babaev</surname><given-names>A. A.</given-names></name> <name><surname>Turovsky</surname><given-names>E. A.</given-names></name></person-group> (<year>2020</year>). <article-title>BDNF overexpression enhances the preconditioning effect of brief episodes of hypoxia, promoting survival of GABAergic neurons</article-title>. <source>Neurosci. Bull.</source> <volume>36</volume>, <fpage>733</fpage>&#x2013;<lpage>760</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12264-020-00480-z</pub-id>, PMID: <pub-id pub-id-type="pmid">32219700</pub-id></mixed-citation></ref>
<ref id="ref99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Den Beucken</surname><given-names>T.</given-names></name> <name><surname>Magagnin</surname><given-names>M. G.</given-names></name> <name><surname>Jutten</surname><given-names>B.</given-names></name> <name><surname>Seigneuric</surname><given-names>R.</given-names></name> <name><surname>Lambin</surname><given-names>P.</given-names></name> <name><surname>Koritzinsky</surname><given-names>M.</given-names></name> <etal/></person-group>. (<year>2011</year>). <article-title>Translational control is a major contributor to hypoxia induced gene expression</article-title>. <source>Radiother. Oncol.</source> <volume>99</volume>, <fpage>379</fpage>&#x2013;<lpage>384</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.radonc.2011.05.058</pub-id></mixed-citation></ref>
<ref id="ref100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X. L.</given-names></name> <name><surname>Su</surname><given-names>B.</given-names></name> <name><surname>Siedlak</surname><given-names>S. L.</given-names></name> <name><surname>Moreira</surname><given-names>P. I.</given-names></name> <name><surname>Fujioka</surname><given-names>H.</given-names></name> <name><surname>Wang</surname><given-names>Y.</given-names></name> <etal/></person-group>. (<year>2008</year>). <article-title>Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins</article-title>. <source>Proc. Natl. Acad. Sci. USA</source> <volume>105</volume>, <fpage>19318</fpage>&#x2013;<lpage>19323</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.0804871105</pub-id></mixed-citation></ref>
<ref id="ref101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westermann</surname><given-names>B.</given-names></name></person-group> (<year>2010</year>). <article-title>Mitochondrial fusion and fission in cell life and death</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source> <volume>11</volume>, <fpage>872</fpage>&#x2013;<lpage>884</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrm3013</pub-id>, PMID: <pub-id pub-id-type="pmid">21102612</pub-id></mixed-citation></ref>
<ref id="ref102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.</given-names></name> <name><surname>Chen</surname><given-names>J. H.</given-names></name> <name><surname>Li</surname><given-names>L.</given-names></name> <name><surname>Gao</surname><given-names>Y. S.</given-names></name> <name><surname>Chen</surname><given-names>J.</given-names></name> <name><surname>Fei</surname><given-names>Z.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>Effect of different mild hypoxia manipulations on kainic acid-induced seizures in the hippocampus of rats</article-title>. <source>Neurochem. Res.</source> <volume>38</volume>, <fpage>123</fpage>&#x2013;<lpage>132</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11064-012-0899-6</pub-id>, PMID: <pub-id pub-id-type="pmid">23065181</pub-id></mixed-citation></ref>
<ref id="ref103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>D. Y.</given-names></name> <name><surname>Ying</surname><given-names>J.</given-names></name> <name><surname>Wang</surname><given-names>X. F.</given-names></name> <name><surname>Zhao</surname><given-names>T. C.</given-names></name> <name><surname>Yoon</surname><given-names>S. T.</given-names></name> <name><surname>Fang</surname><given-names>Y.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Mitochondrial dynamics: a key role in neurodegeneration and a potential target for neurodegenerative disease</article-title>. <source>Front. Neurosci.</source> <volume>15</volume>:<fpage>654785</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnins.2021.654785</pub-id>, PMID: <pub-id pub-id-type="pmid">33912006</pub-id></mixed-citation></ref>
<ref id="ref104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yapa</surname><given-names>N. M. B.</given-names></name> <name><surname>Lisnyak</surname><given-names>V.</given-names></name> <name><surname>Reljic</surname><given-names>B.</given-names></name> <name><surname>Ryan</surname><given-names>M. T.</given-names></name></person-group> (<year>2021</year>). <article-title>Mitochondrial dynamics in health and disease</article-title>. <source>FEBS Lett.</source> <volume>595</volume>, <fpage>1184</fpage>&#x2013;<lpage>1204</lpage>. doi: <pub-id pub-id-type="doi">10.1002/1873-3468.14077</pub-id>, PMID: <pub-id pub-id-type="pmid">33742459</pub-id></mixed-citation></ref>
<ref id="ref105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>Z.</given-names></name> <name><surname>Burger</surname><given-names>N.</given-names></name> <name><surname>Kula-Alwar</surname><given-names>D.</given-names></name> <name><surname>Aksentijevi&#x0107;</surname><given-names>D.</given-names></name> <name><surname>Bridges</surname><given-names>H. R.</given-names></name> <name><surname>Prag</surname><given-names>H. A.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Structural basis for a complex I mutation that blocks pathological ROS production</article-title>. <source>Nat. Commun.</source> <volume>12</volume>:<fpage>707</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41467-021-20942-w</pub-id></mixed-citation></ref>
<ref id="ref106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhan</surname><given-names>L. X.</given-names></name> <name><surname>Wang</surname><given-names>T.</given-names></name> <name><surname>Li</surname><given-names>W.</given-names></name> <name><surname>Xu</surname><given-names>Z. C.</given-names></name> <name><surname>Sun</surname><given-names>W. W.</given-names></name> <name><surname>Xu</surname><given-names>E.</given-names></name></person-group> (<year>2010</year>). <article-title>Activation of Akt/FoxO signaling pathway contributes to induction of neuroprotection against transient global cerebral ischemia by hypoxic pre-conditioning in adult rats</article-title>. <source>J. Neurochem.</source> <volume>114</volume>, <fpage>897</fpage>&#x2013;<lpage>908</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1471-4159.2010.06816.x</pub-id>, PMID: <pub-id pub-id-type="pmid">20492357</pub-id></mixed-citation></ref>
<ref id="ref107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J. H.</given-names></name> <name><surname>Qian</surname><given-names>H.</given-names></name> <name><surname>Zhao</surname><given-names>P.</given-names></name> <name><surname>Hong</surname><given-names>S. S.</given-names></name> <name><surname>Xia</surname><given-names>Y.</given-names></name></person-group> (<year>2006</year>). <article-title>Rapid hypoxia preconditioning protects cortical neurons from glutamate toxicity through delta-opioid receptor</article-title>. <source>Stroke</source> <volume>37</volume>, <fpage>1094</fpage>&#x2013;<lpage>1099</lpage>. doi: <pub-id pub-id-type="doi">10.1161/01.STR.0000206444.29930.18</pub-id>, PMID: <pub-id pub-id-type="pmid">16514101</pub-id></mixed-citation></ref>
<ref id="ref108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>R. R.</given-names></name> <name><surname>Xu</surname><given-names>M. X.</given-names></name> <name><surname>Wang</surname><given-names>Y.</given-names></name> <name><surname>Xie</surname><given-names>F.</given-names></name> <name><surname>Zhang</surname><given-names>G.</given-names></name> <name><surname>Qin</surname><given-names>X. Y.</given-names></name></person-group> (<year>2017</year>). <article-title>Nrf2-a promising therapeutic target for defensing against oxidative stress in stroke</article-title>. <source>Mol. Neurobiol.</source> <volume>54</volume>, <fpage>6006</fpage>&#x2013;<lpage>6017</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12035-016-0111-0</pub-id>, PMID: <pub-id pub-id-type="pmid">27696223</pub-id></mixed-citation></ref>
<ref id="ref109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhen</surname><given-names>J. L.</given-names></name> <name><surname>Wang</surname><given-names>W. P.</given-names></name> <name><surname>Zhou</surname><given-names>J. J.</given-names></name> <name><surname>Qu</surname><given-names>Z. Z.</given-names></name> <name><surname>Fang</surname><given-names>H. B.</given-names></name> <name><surname>Zhao</surname><given-names>R. R.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Chronic intermittent hypoxic preconditioning suppresses pilocarpine-induced seizures and associated hippocampal neurodegeneration</article-title>. <source>Brain Res.</source> <volume>1563</volume>, <fpage>122</fpage>&#x2013;<lpage>130</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.brainres.2014.03.032</pub-id>, PMID: <pub-id pub-id-type="pmid">24680745</pub-id></mixed-citation></ref>
<ref id="ref110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zorov</surname><given-names>D. B.</given-names></name> <name><surname>Juhaszova</surname><given-names>M.</given-names></name> <name><surname>Sollott</surname><given-names>S. J.</given-names></name></person-group> (<year>2014</year>). <article-title>Mitochondrial reactive oxygen species (Ros) and Ros-induced Ros release</article-title>. <source>Physiol. Rev.</source> <volume>94</volume>, <fpage>909</fpage>&#x2013;<lpage>950</lpage>. doi: <pub-id pub-id-type="doi">10.1152/physrev.00026.2013</pub-id>, PMID: <pub-id pub-id-type="pmid">24987008</pub-id></mixed-citation></ref>
</ref-list><fn-group><fn id="fn0001" fn-type="custom" custom-type="edited-by"><p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/428898/overview">Sudhanshu P. Raikwar</ext-link>, Barrow Neurological Institute (BNI), United States</p></fn>
<fn id="fn0002" fn-type="custom" custom-type="reviewed-by"><p>Reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2590240/overview">Amanda Alves Marcelino Da Silva</ext-link>, Universidade de Pernambuco, Brazil</p><p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2925949/overview">Ajeena Ramanujan</ext-link>, University of Texas MD Anderson Cancer Center, United States</p><p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1123654/overview">Mercedes Garc&#x00ED;a-Roche</ext-link>, Universidad de la Rep&#x00FA;blica, Uruguay</p><p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1572874/overview">Kasja Pavlovi&#x0107;</ext-link>, University of Belgrade, Serbia</p></fn></fn-group></back>
</article>